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1. 
ANTIBODIES WITH INCREASED 
AFFINITIES FOR ANTHRAX ANTIGENS 
This application is a divisional of U.S. Patent Application 
Ser. No. 10/620,049, filed Jul. 15, 2003, now U.S. Pat. No. 
6,916,474 which application claims the priority of U.S. Pro 
visional Patent App. No. 60/396,058, filed Jul. 15, 2002, the 
entire disclosures of which are incorporated herein by refer 
CCC. 
This invention was made with government Support under 
contract number DAAD19-99-1-0207 awarded by the Army 
Research Office, and contract number DAAD 17-01-D-0001 
awarded by the Army Research Laboratory. The government 
has certain rights in the invention. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates generally to the field of pro 
tein engineering. More particularly, it concerns antibodies 
that immunologically bind with improved affinity to a Bacil 
lus anthracis antigen. 
2. Description of Related Art 
The isolation of polypeptides that either bind to ligands 
with high affinity and specificity or catalyze the enzymatic 
conversion of a reactant (Substrate) into a desired product is a 
key process in biotechnology. Ligand-binding polypeptides, 
including proteins and enzymes with a desired substrate 
specificity can be isolated from large libraries of mutants, 
provided that a suitable screening method is available. Small 
protein libraries composed of 10-10 distinct mutants can be 
screened by first growing each clone separately and then 
using a conventional assay for detecting clones that exhibit 
specific binding. For example, individual clones expressing 
different protein mutants can be grown in microtiter well 
plates or separate colonies on semisolid media such as agar 
plates. To detect binding the cells are lysed to release the 
proteins and the lysates are transferred to nylon filters, which 
are then probed using radiolabeled or fluorescently labeled 
ligands (DeWildt et al. 2000). However, even with robotic 
automation and digital image systems for detecting binding in 
high density arrays, it is not feasible to screen large libraries 
consisting oftens of millions or billions of clones. The screen 
ing of libraries of that size is required for the denovo isolation 
of enzymes or protein binders that have affinities in the sub 
nanomolar range. 
The screening of very large protein libraries has been 
accomplished by a variety of techniques that rely on the 
display of proteins on the surface of viruses or cells. The 
underlying premise of display technologies is that proteins 
engineered to be anchored on the external Surface of biologi 
cal particles (i.e., cells or viruses) are directly accessible for 
binding to ligands without the need for lysing the cells. 
Viruses or cells displaying proteins with affinity for a ligand 
can be isolated in a variety of ways including sequential 
adsorption/desorption form immobilized ligand, by magnetic 
separations or by flow cytometry (U.S. Pat. Nos. 5.223,409, 
5,837,500, Georgiou et al. 1997, Shusta et al. 1999). 
The most widely used display technology for protein 
library screening applications is phage display. Phage display 
is a well-established and powerful technique for the discovery 
of proteins that bind to specific ligands and for the engineer 
ing of binding affinity and specificity (Rodi and Makowski, 
1999). In phage display, a gene of interest is fused in-frame to 
phage genes encoding Surface-exposed proteins, most com 
monly pl. The gene fusions are translated into chimeric 













displaying a protein with binding affinity for a ligand can be 
readily enriched by selective adsorption onto immobilized 
ligand, a process known as “panning. The bound phage is 
desorbed from the Surface, usually by acid elution, and ampli 
fied through infection of E. coli cells. Usually, 4-6 rounds of 
panning and amplification are sufficient to select for phage 
displaying specific polypeptides, even from very large librar 
ies with diversities up to 10". Several variations of phage 
display for the rapid enrichment of clones displaying tightly 
binding polypeptides have been developed (Duenas and Bor 
rebaeck, 1994; Malmborg et al., 1996; Kjaer et al., 1998: 
Burioni et al., 1998: Levitan, 1998; Mutuberria et al., 1999; 
Johns et al., 2000). 
One of the most significant applications of phage display 
technology has been the isolation of high affinity antibodies 
(Dall’Acqua and Carter, 1998; Hudson et al., 1998: Hoogen 
boom et al., 1998; Maynard and Georgiou, 2000). Very large 
and structurally diverse libraries of ScFv or F fragments 
have been constructed and have been used successfully for the 
in vitro isolation of antibodies to a multitude of both synthetic 
and natural antigens (Griffith et al., 1994; Vaughan et al., 
1996; Sheets et al., 1998; Pini et al., 1998; de Haard et al., 
1999: Knappik et al., 2000; Sblattero and Bradbury, 2000). 
Antibody fragments with improved affinity or specificity can 
be isolated from libraries in which a chosen antibody had 
been subjected to mutagenesis of either the CDRs or of the 
entire gene CDRs (Hawkins et al., 1992; Thompson et al., 
1996; Chowdhury and Pastan, 1999). Finally, the expression 
characteristics of schv, notorious for their poor solubility, 
have also been improved by phage display of mutant libraries 
(Deng et al., 1994; Coia et al., 1997). 
However, several spectacular successes notwithstanding, 
the screening of phage-displayed libraries can be complicated 
by a number of factors. First, phage display imposes minimal 
selection for properexpression in bacteria by virtue of the low 
expression levels of antibody fragment gene III fusion nec 
essary to allow phage assembly and yet Sustain cell growth 
(Krebber et al., 1996, 1997). As a result, the clones isolated 
after several rounds of panning are frequently difficult to 
produce on a preparative scale in E. coli. Second, although 
phage displayed proteins may bind a ligand, in some cases 
their un-fused soluble counterparts may not (Griep et al., 
1999). Third, the isolation of ligand-binding proteins and 
more specifically antibodies having high binding affinities 
can be complicated by avidity effects by virtue of the need for 
gene III protein to be present at around 5 copies per virion to 
complete phage assembly. Even with systems that result in 
predominantly monovalent protein display, there is nearly 
always a small fraction of clones that contain multiple copies 
of the protein. Such clones bind to the immobilized surface 
more tightly and are enriched relative to monovalent phage 
with higher affinities (Deng et al., 1995; MacKenzie et al., 
1996, 1998). Fourth, theoretical analysis aside (Levitan, 
1998), panning is still a “blackbox” process in that the effects 
of experimental conditions, for example the Stringency of 
washing steps to remove weakly or non-specifically bound 
phage, can only be determined by trial and error based on the 
final outcome of the experiment. Finally, eventhoughp|II and 
to a lesser extent the other proteins of the phage coat are 
generally tolerant to the fusion of heterologous polypeptides, 
the need to be incorporated into the phage biogenesis process 
imposes biological constraints that can limit library diversity. 
Therefore, there is a great need in the art for techniques 
capable of overcoming these limitations. 
Protein libraries have also been displayed on the surface of 
bacteria, fungi, or higher cells. Cell displayed libraries are 
typically screened by flow cytometry (Georgiou et al. 1997, 
US 7,902,344 B2 
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Daugherty et al. 2000). However, just as in phage display, the 
protein has to be engineered for expression on the outer cell 
surface. This imposes several potential limitations. For 
example, the requirement for display of the protein on the 
Surface of a cell imposes biological constraints that limit the 
diversity of the proteins and protein mutants that can be 
screened. Also, complex proteins consisting of several 
polypeptide chains cannot be readily displayed on the Surface 
of bacteria, filamentous phages or yeast. As such, there is a 
great need in the art for technology which circumvents all the 
above limitations and provides an entirety novel means for the 
screening of very large polypeptide libraries. 
The use of techniques allowing creation of antibodies with 
improved affinities to anthrax antigens in particular is needed. 
Anthrax (B. anthracis) is a Zoonotic soil organism endemic to 
many parts of the world. Infection through the inhalation of 
the heat resistant spores of the Gram positive bacterium, B. 
anthracis, results in up to 80% mortality rate if left untreated 
(Shafazand, 1999). In fact, B. anthracis was one of the first 
biological warfare agents to be developed and continues to be 
perceived as a major threat. While vaccine strains have been 
developed, widespread use is neither available nor recom 
mended by the CDC. 
Following inhalation, the B. anthracis spores germinate in 
the alveolar macrophages and migrate to lymph nodes where 
they multiply and enter the bloodstream, quickly reaching 
107-10 organisms permilliliter of blood (Dixonet al., 1999). 
The vegetative bacteria excrete a tripartite exotoxin that is 
responsible for the etiology of the disease. The toxin is an 83 
kDa polypeptide, protective antigen (PA), that binds to a 
recently identified receptor on the Surface of macrophages 
(Bradley et al., 2001). Identification of improved antibodies 
specific for anthrax antigens would offer the potential for new 
and improved therapeutic and diagnostic regimens and thus 
represent an important advance. 
SUMMARY OF THE INVENTION 
In one aspect, the invention provides an isolated antibody 
or fragment thereof that binds immunologically to Bacillus 
anthracis protective antigen with an affinity Kd of between 
about 140 pM and about 21 pM as determined by surface 
plasmon resonance. Such an antibody or fragment thereof 
may be further defined as binding immunologically to Bacil 
lus anthracis protective antigen with a binding affinity Kd of 
between about 96 pMandabout 21 pMand/or between about 
35 pM and about 21 pM. The isolated antibody or fragment 
thereof may still further be defined as comprising an Fc 
domain of IgA, Ig), IgE, IgG or IgM. The antibody may be a 
humanized antibody and may be a human antibody. In certain 
embodiments, the isolated antibody or fragment thereof.com 
prises an ScV fragment and antibody constant regions form 
ing a monovalent antibody portion of at least 40 kDa. 
In another aspect, the invention provides an isolated anti 
body or fragment thereof that binds immunologically to 
Bacillus anthracis protective antigen and comprises the vari 
able light and variable heavy chain of SEQID NO:21, with 
the exception that the variable light and variable heavy chain 
comprise a modification selected from the group consisting 
of I21V, S22G, L33S, Q38R, L46F, Q55L, S56P. T74A, 
S76N, Q78L, L94P S7P. K19R, S30N, T57S, K62R, K64E, 
T681, and M80L, wherein said I21V, S22G, L33S, Q38R, 
L46F, Q55L, S56P. T74A, S76N, Q78L and L94P are in the 
variable light chain and wherein said S7P. K19R, S30N, 
T57S, K62R, K64E,T681 and M80L are in the variable heavy 
chain. In certain embodiments of the invention, the isolated 













from about two to at all of said modifications, including about 
3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or all of the 
modifications, including all possible combinations of the 
foregoing modifications. 
In certain aspects of the invention, the isolated antibody or 
fragment thereof is further defined as binding immunologi 
cally to Bacillus anthracis protective antigen with an affinity 
Kd of between about 140 pMandabout 21 pMas determined 
by surface plasmon resonance. In further embodiments of the 
invention the antibody or fragment thereof comprises Q55L 
and S56P. The isolated antibody or fragment thereof may 
comprising the variable light and/or variable heavy chain of 
SEQ ID NO:22 or SEQ ID NO:24. In one embodiment, the 
isolated antibody or fragment thereof comprises SEQ ID 
NO:22 and/or SEQID NO:24. The isolated antibody or frag 
ment thereof may be further defined as a scAb, Fab or SFv and 
may also be further defined as comprising an Fc domain of 
IgA, Ig|D, IgE, IgG or IgM. The isolated antibody or fragment 
thereof may be a humanized antibody and may be human. In 
particular embodiments, the isolated antibody or fragment 
thereof comprises an Schv fragment and antibody constant 
regions forming a monovalent antibody portion of at least 40 
kDa. 
In yet another aspect, the invention provides an isolated 
nucleic acid encoding an antibody or fragment thereof pro 
vided by the invention. In one embodiment, the nucleic acid 
encodes the variable light chain of SEQ ID NO:23 and/or 
SEQ ID NO:25. In another embodiment, the nucleic acid 
encodes the variable heavy chain of SEQID NO:23 and/or 
SEQ ID NO:25. In yet another embodiment, nucleic acid 
encodes the polypeptide of SEQ ID NO:23 and, in another 
embodiment, the polypeptide of SEQID NO:25. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The following drawings form part of the present specifica 
tion and are included to further demonstrate certain aspects of 
the present invention. The invention may be better understood 
by reference to one or more of these drawings in combination 
with the detailed description of specific embodiments pre 
sented herein. 
FIGS. 1A-B: Detection of ScFVs for Larger Target Antigen 
conjugated fluorophores. 
FIG. 2: Examples of targets visualized by APEX. (A) Fluo 
rescence distribution of ABLECTM cells expressing PA spe 
cific (14B7) and digoxigenin specific (Dig) schv and labeled 
with 200 nM BodipyTM conjugated fluorescent antigens. His 
tograms represent the mean fluorescence intensity of 10,000 
E. coli events. (B) Histograms of cells expressing 14B7 or Dig 
sch V labeled with 200 nM of the 240kDa digoxigenin-phy 
coerythrin conjugate. 
FIG. 3: Analysis of anti-PA antibody fragments selected 
using APEX (A) Signal Plasmon Resonance (SPR) analysis of 
anti-PA scAb binding to PA. (B) Table of affinity data 
acquired by SPR. (C) FC Histogram of anti-PA schv in 
pAPEX1 expressed in E. coli and labeled with 200 nM PA 
BodipyTM conjugate as compared with anti-methamphet 
amine (Meth) scFv negative control. 
FIG. 4: N-Terminal vs. C-Terminal anchoring strategy 
comparison. (A) Anti-digoxigenin Dig Scfv, anti-PA M18 
schv and anti-methamphetamine Meth schv expressed as 
N-terminal fusions in the p APEX1 vector in E. coli specifi 
cally label with 200 nM of their respective antigen. (B) C-ter 
minal fusions of same scFv in pAK200 vector specifically 
labeled with 200nM of their respective antigen. 
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FIG. 5: View from the top of the antibody binding pocket 
showing the conformation and amino acid substitutions in the 
1H, M5, M6 and M18 sequences. 
FIG. 6: Alignment of 14-B7 schv (SEQID NO:21) and M18 
schv (SEQID NO:23) sequences showing variable heavy and 
variable light chains and mutations made to improve binding 
affinity. 
DESCRIPTION OF ILLUSTRATIVE 
EMBODIMENTS 
The invention overcomes the limitations of the prior art by 
providing improved antibodies created using a novel method 
for isolating binding polypeptides. In the technique used, a 
library of polypeptide (e.g., antibody or other binding 
polypeptides) mutants can be constructed and expressed in 
Gram negative bacteria. The mutant polypeptides can be 
expressed as fusion proteins that are anchored on the inner 
(cytoplasmic) membrane of the bacterium facing the peri 
plasm. 
The antibodies isolated bind immunologically to Bacillus 
anthracis protective antigen with a 120 fold improvement in 
affinity over the starting antibody. The antibodies have impor 
tant clinical and diagnostic applications. Infections due to 
Bacillus anthracis, commonly referred to as anthrax, most 
commonly occur in hoofed mammals, but serious forms of 
human anthrax include inhalation anthrax, cutaneous 
anthrax, and intestinal anthrax. Inhalation anthrax is usually 
fatal. The intestinal disease form of anthrax may follow the 
consumption of contaminated food and is characterized by an 
acute inflammation of the intestinal tract. Direct person-to 
person spread of anthrax is extremely unlikely, if it occurs at 
all. Therefore, the CDC explains that there is no need to 
immunize or treat contacts of persons ill with anthrax, such as 
household contacts, friends, or co-workers, unless they also 
were also exposed to the same source of the infection. 
For persons infected with anthrax, treatment Success is 
limited by several factors. Such as the increased incidence of 
antibiotic resistance and treatment delays that lessen the 
chance of survival. It is known that early treatment of anthrax 
with antibiotics is essential to reduce mortality—delays in 
treatment profoundly decrease survival rates. Early treat 
ment, however, is difficult because initial symptoms of the 
infection, e.g., when the bacterial spores are inhaled, hereto 
fore known as inhalation anthrax, may resemble those of the 
common cold. In addition, symptoms of anthrax infection, 
depending on how the bacterium is contracted, may take 
seven to sixty days to appear. 
The pathogenicity of B. anthracis is expressed in two ways: 
a toxic effect made evident by the appearance of an edema, 
and a so-called lethal toxic effect that may lead to the death of 
the subject infected. These effects are attributed to the pres 
ence of toxins produced by a combination of three protein 
factors present in B. anthracis. In both humans and mammals, 
toxins will increase in the body even during early stages of 
infection when the host appears asymptomatic. This explains 
why delays in treatment can be fatal. Thus, there is not only a 
critical need for better anthrax intervention therapies, but a 
critical need for point-of-care, rapid, and extremely sensitive 
diagnostic tests to establish the presence of anthrax early in 
the infection. 
Passive immunization in an effort to neutralize toxins with 
antibodies, usually polyclonal antibodies, has been used as a 
therapeutic intervention for a variety of bacterial infections 
(Keller and Stiehm, 2000). A major limitation of using poly 
clonal antisera in patients is the possibility of "serum sick 














from a different species. In addition, higher affinity antibod 
ies are more effective for toxin neutralization, but there is no 
general way to enhance intentionally the affinity of poly 
clonal sera or even monoclonal antibodies derived from 
hybridomas. 
I. Antibodies and Use Thereof 
The identification of high affinity engineered antibodies is 
an important advance. In accordance with the invention, an 
antibody includes any portion or fragment of an antibody, 
e.g., an Schv fragment. The antibody may be of any antibody 
class. The antibody may be, e.g., derived from an Schv frag 
ment which further includes antibody constant regions to 
create monovalent antibody portion of, e.g., at least 40 kDa. 
The antibody may be affinity matured by selecting for clones 
having higher affinity than the wild-type antibody sequence 
cloned from a hybridoma after imperfect PCR amplification, 
e.g., error-prone expression libraries. 
In one embodiment, an isolated antibody or fragment 
thereof may bind immunologically to Bacillus anthracis pro 
tective antigen with an affinity Kd of between about 140 pM 
and about 21 pM as determined by Surface plasmon reso 
nance. Such an antibody or fragment thereof may be further 
defined as binding immunologically to Bacillus anthracis 
protective antigen with a binding affinity Kd of between about 
96 pM and about 21 pM and/or between about 35 pM and 
about 21 pM. 
Affinity matured antibodies or portions thereof may be 
fused to create divalent homodimeric antibodies. The anti 
body or portions thereof may generally confer protection to a 
host against Bacillus anthracis toxin. The host may be, e.g., a 
human and exhibit, in one example, about a one-to-one sto 
ichiometry. The present invention therefore includes a 
method of treating a host having or at risk of infection by 
Bacillus anthracis, the method comprising the step of admin 
istering to a host a composition comprising an antibody or 
fragment thereof provided by the invention. The composition 
may be administered after onset of symptoms or may be 
administered prophylactically. The antibodies of the inven 
tion may also find diagnostic use, for example, to detect 
exposure to anthrax. 
II. Anchored Periplasmic Expression 
Prior art methods of both phage display and bacterial cell 
surface display suffer from a limitation in that the protein is 
required, by definition, to be physically. displayed on the 
outer surface of the vehicle used, to allow unlimited access to 
the targets (immobilized for phage or fluorescently conju 
gated ligands for flow cytometry) (U.S. Pat. No. 5,223,409, 
the disclosure of which is specifically incorporated herein by 
reference in its entirety). However, certain proteins are known 
to be poorly displayed on phage (Maenaka et al., 1996; Corey 
et al., 1993) and the toxic effects of outer cell surface display 
have been treated at length (Daugherty et al., 1999). Further, 
there is no lipopolysaccharide to interfere with binding on the 
inner membrane. 
Herein, the inventors have isolated improved antibodies 
using a technique in which binding proteins can be expressed 
on the periplasmic face of the inner membrane as fusion 
proteins yet still be accessible to relatively large ligands. As 
used herein, the term “binding polypeptide' includes not only 
antibodies, but also fragments of antibodies, as well as any 
other peptides, including proteins potentially capable of bind 
ing a given target molecule. The antibody or other binding 
peptides may be expressed with the invention as fusion 
polypeptides with polypeptides capable of serving as anchors 
to the periplasmic face of the inner membrane. Such a tech 
nique may be termed Anchored Periplasmic Expression” or 
“APEX. 
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The periplasmic compartment is contained between the 
inner and outer membranes of Gram negative cells. As a 
Sub-cellular compartnent, it is subject to variations in size, 
shape and content that accompany the growth and division of 
the cell. Within a framework of peptidoglycan heteroploymer 
is a dense mileau of periplasmic proteins and little water, 
lending a gel-like consistency to the compartment (Hobot et 
al., 1984; Van Wielink and Duine, 1990). The peptidoglycan 
is polymerized to different extents depending on the proxim 
ity to the outer membrane, close-up it forms the murein sac 
culus that affords cell shape and resistance to osmotic lysis. 
The outer membrane (see Nikaido, 1996) is composed of 
phospholipids, porin proteins and, extending into the 
medium, lipopolysaccharide (LPS). The molecular basis of 
outer membrane integrity resides with LPS ability to bind 
divalent cations (Mg2+ and Ca2+) and link each other elec 
trostatically to form a highly ordered quasi-crystalline 
ordered “tiled roof on the surface (Labischinski et al., 1985). 
The membrane forms a very strict permeability barrier allow 
ing passage of molecules no greater than around 650 Da 
(Burman et al., 1972; Decad and Nikaido, 1976) via the 
porins. The large water filled porin channels are primarily 
responsible for allowing free passage of mono and disaccha 
rides, ions and amino acids in to the periplasm compartment 
(Nakae, 1976: Nikaido and Nakae, 1979; Nikaido and Vaara, 
1985). With such strict physiological regulation of access by 
molecules to the periplasm it may appear, at first glance, 
inconceivable that APEX should work unless the ligands 
employed are at or below the 650 Da exclusion limit or are 
analogues of normally permeant compounds. However, the 
inventors have shown that ligands greater than 2000 Dain size 
can diffuse into the periplasm without disruption of the peri 
plasmic membrane. Such diffusion can be aided by one or 
more treatments of a bacterial cell, thereby rendering the 
outer membrane more permeable, as is described herein 
below. 
III. Screening Candidate Molecules 
The present inventors employed techniques for identifying 
molecules capable of binding a target ligand. The binding 
polypeptides screened may comprise large libraries of diverse 
candidate Substances, or, alternatively, may comprise particu 
lar classes of compounds selected with an eye towards struc 
tural attributes that are believed to make them more likely to 
bind the target ligand. In one embodiment of the invention, 
the candidate binding protein is an antibody, or a fragment or 
portion thereof. In other embodiments of the invention, the 
candidate molecule may be another binding protein. 
To identify a candidate molecule capable of binding a 
target ligand, one may carry out the steps of providing a 
population of Gram negative bacterial cells comprising 
fusion proteins between candidate binding polypeptides and a 
sequence anchored to the periplasmic face of the inner mem 
brane; admixing the bacteria and at least a first labeled target 
ligand capable of contacting the candidate binding polypep 
tide and identifying at least a first bacterium expressing a 
molecule capable of binding the target ligand. 
In the aforementioned method, the binding between the 
anchored candidate binding protein and the labeled ligand 
will prevent diffusing out of the cell. In this way, molecules of 
the labeled ligand can be retained in the periplasm of the 
bacterium. Alternatively, the periplasm can be removed, 
whereby the anchoring will cause retention of the bound 
candidate molecule. The labeling may then be used to isolate 
the cell expressing a binding polypeptide capable of binding 
the target ligand, and in this way, the gene encoding the 
binding polypeptide isolated. The molecule capable of bind 














using in vivo orex vivo expression methods, and then used for 
any desired application, for example, for diagnostic or thera 
peutic applications, as described below. 
As used herein the term “candidate molecule' or “candi 
date polypeptide' refers to any molecule or polypeptide that 
may potentially have affinity for a target ligand. The candi 
date Substance may be a protein or fragment thereof, includ 
ing a small molecule Such as synthetic molecule. The candi 
date molecule may in one embodiment of the invention, 
comprise an antibody sequence or fragment thereof. Such 
sequences may be particularly designed for the likelihood 
that they will bind a target ligand. 
Binding polypeptides or antibodies isolated in accordance 
with the invention also may help ascertain the structure of a 
target ligand. In principle, this approach yields a pharmacore 
upon which Subsequent drug design can be based. It is pos 
sible to bypass protein crystallography altogether by gener 
ating anti-idiotypic antibodies to a functional, pharmacologi 
cally active antibody. As a mirror image of a mirror image, the 
binding site of anti-idiotype would be expected to be an 
analog of the original antigen. The anti-idiotype could then be 
used to identify and isolate peptides from banks of chemi 
cally- or biologically-produced peptides. Selected peptides 
would then serve as the pharmacore. Anti-idiotypes may be 
generated using the methods described herein for producing 
antibodies, using an antibody as the antigen. On the other 
hand, one may simply acquire, from various commercial 
sources, small molecule libraries that are believed to meet the 
basic criteria for binding the target ligand. Such libraries 
could be provided by way of nucleic acids encoding the Small 
molecules or bacteria expressing the molecules. 
A. Cloning of Binding Protein Coding Sequences 
The binding affinity of an antibody or other binding protein 
can, for example, be determined by the Scatchard analysis of 
Munson & Pollard (1980). After a bacterial cell is identified 
that produces molecules of the desired specificity, affinity, 
and/or activity, the corresponding coding sequence may be 
cloned. In this manner, DNA encoding the molecule can be 
isolated and sequenced using conventional procedures (e.g., 
by using oligonucleotide probes that are capable of binding 
specifically to genes encoding the antibody or binding pro 
tein). 
Once isolated, the antibody or binding protein DNA may 
be placed into expression vectors, which can then transfected 
into host cells such as simian COS cells, Chinese hamster 
ovary (CHO) cells, or myeloma cells that do not otherwise 
produce immunoglobulin protein, to obtain the synthesis of 
binding protein in the recombinant host cells. The DNA also 
may be modified, for example, by Substituting the coding 
sequence for human heavy and light chain constant domains 
in place of the homologous murine sequences (Morrison, et 
al., 1984), or by. covalently joining to the immunoglobulin 
coding sequence all or part of the coding sequence for a 
non-immunoglobulin polypeptide. In that manner, “chi 
meric' or “hybrid binding proteins are prepared that have the 
desired binding specificity. 
Typically, such non-immunoglobulin polypeptides are 
substituted for the constant domains of an antibody, or they 
are substituted for the variable domains of one antigen-com 
bining site of an antibody to create a chimeric bivalent anti 
body comprising one antigen-combining site having specific 
ity for the target ligand and another antigen-combining site 
having specificity for a different antigen. 
Chimeric or hybrid antibodies also may be prepared in 
vitro using known methods in synthetic protein chemistry, 
including those involving crosslinking agents. For example, 
immunotoxins may be constructed using a disulfide exchange 
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reaction or by forming a thioether bond. Examples of suitable 
reagents for this purpose include iminothiolate and methyl 
4-mercaptobutyrimidate. 
It will be understood by those of skill in the art that nucleic 
acids may be cloned from viable or inviable cells. In the case 
of inviable cells, for example, it may be desired to use ampli 
fication of the cloned DNA, for example, using PCR. This 
may also be carried out using viable cells either with or 
without further growth of cells. 
B. Maximization of Protein Affinity for Ligands 
In a natural immune response, antibody genes accumulate 
mutations at a high rate (somatic hypermutation). Some of the 
changes introduced will confer higher affinity, and B cells 
displaying high-affinity Surface immunoglobulin. This natu 
ral process can be mimicked by employing the technique 
known as “chain shuffling” (Marks et al., 1992). In this 
method, the affinity of “primary' human antibodies obtained 
in accordance with the invention could be improved by 
sequentially replacing the heavy and light chain V region 
genes with repertoires of naturally occurring variants (reper 
toires) of V domain genes obtained from unimmunized 
donors. This technique allows the production of antibodies 
and antibody fragments with affinities in the nM range. A 
strategy for making very large antibody repertoires was 
described by Waterhouse et al., (1993), and the isolation of a 
high affinity human antibody directly from Such large phage 
library was reported by Griffith et al., (1994). Gene shuffling 
also can be used to derive human antibodies from rodent 
antibodies, where the human antibody has similar affinities 
and specificities to the starting rodent antibody. According to 
this method, which is also referred to as “epitope imprinting, 
the heavy or light chain V domain gene of rodent antibodies 
obtained by the phage display technique is replaced with a 
repertoire of human V domain genes, creating rodent-human 
chimeras. Selection of the antigen results in isolation of 
human variable regions capable of restoring a functional anti 
gen-binding site, i.e. the epitope governs (imprints) the 
choice of partner. When the process is repeated in order to 
replace the remaining rodent V domain, a human antibody is 
obtained (see PCT patent application WO 93/06213, pub 
lished Apr. 1, 1993). Unlike traditional humanization of 
rodent antibodies by CDR grafting, this technique provides 
completely human antibodies, which have no framework or 
CDR residues of rodent origin. 
C. Labeled Ligands 
In one embodiment of the invention, an antibody orbinding 
protein is isolated which has affinity for a labeled ligand. By 
permeabilization and/or removal of the periplasmic mem 
brane of a Gram negative bacterium in accordance with the 
invention, labeled ligands of potentially any size could be 
screened. In the absence of removal of the periplasmic mem 
brane, it will typically be preferable that the labeled ligand is 
less that 50,000 Dain size in order to allow efficient diffusion 
of the ligand across the bacterial periplasmic membrane. 
As indicated above, it will typically be desired in accor 
dance with the invention to provide a ligand which has been 
labeled with one or more detectable agent(s). This can be 
carried out, for example, by linking the ligand to at least one 
detectable agent to form a conjugate. For example, it is con 
ventional to link or covalently bind or complex at least one 
detectable molecule or moiety. A “label” or “detectable label' 
is a compound and/or element that can be detected due to 
specific functional properties, and/or chemical characteris 
tics, the use of which allows the ligand to which it is attached 
to be detected, and/or further quantified if desired. Examples 
of labels which could be used with the invention include, but 













labels, phosphorescent molecules, chemiluminescent mol 
ecules, chromophores, luminescent molecules, photoaffinity 
molecules, colored particles or ligands, such as biotin. 
In one embodiment of the invention, a visually-detectable 
marker is used such that automated screening of cells for the 
label can be carried out. In particular, fluorescent labels are 
beneficial in that they allow use of flow cytometry for isola 
tion of cells expressing a desired binding protein orantibody. 
Examples of agents that may be detected by visualization 
with an appropriate instrument are known in the art, as are 
methods for their attachment to a desired ligand (see, e.g., 
U.S. Pat. Nos. 5,021,236: 4,938,948; and 4,472,509, each 
incorporated herein by reference). Such agents can include 
paramagnetic ions; radioactive isotopes; fluorochromes; 
NMR-detectable substances and substances for X-ray imag 
ing. Types of fluorescent labels that may be used with the 
invention will be well known to those of skill in the art and 
include, for example, Alexa 350, Alexa 430, AMCA, 
BODIPY 630/650, BODIPY 650/665, BODIPY-FL, 
BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, Cascade 
Blue, Cy3, Cy5,6-FAM, Fluorescein Isothiocyanate, HEX, 
6-JOE, Oregon Green 488, Oregon Green 500, Oregon Green 
514, Pacific Blue, REG, Rhodamine Green, Rhodamine Red, 
Renographin, ROX, TAMRA, TET. Tetramethylrhodamine, 
and/or Texas Red. 
Magnetic screening techniques are well known to those of 
skill in the art (see, for example, U.S. Pat. Nos. 4.988,618, 
5,567.326 and 5,779,907). Examples of paramagnetic ions 
that could be used as labels in accordance with such tech 
niques include ions such as chromium (III), manganese (II), 
iron (III), iron (II), cobalt(II), nickel(II), copper(II), neody 
mium (III), samarium (III), ytterbium (III), gadolinium (III), 
vanadium (II), terbium (III), dysprosium (III), holmium (III) 
and/or erbium (III). Ions useful in other contexts include but 
are not limited to lanthanum (III), gold (III), lead (II), and 
especially bismuth(III). 
Another type of ligand conjugate contemplated in the 
present invention are those where the ligand is linked to a 
secondary binding molecule and/or to an enzyme (an enzyme 
tag) that will generate a colored product upon contact with a 
chromogenic Substrate. Examples of Such enzymes include 
urease, alkaline phosphatase, (horseradish) hydrogen peroxi 
dase or glucose oxidase. In Such instances, it will be desired 
that cells selected remain viable. Preferred secondary binding 
ligands are biotin and/or avidin and streptavidin compounds. 
The use of such labels is well known to those of skill in the art 
and are described, for example, in U.S. Pat. Nos. 3,817.837; 
3.850,752; 3,939,350; 3,996.345; 4,277,437; 4,275,149 and 
4.366,241; each incorporated herein by reference. 
Molecules containing azido groups also may be used to 
form covalent bonds to proteins through reactive nitrene 
intermediates that are generated by low intensity ultraviolet 
light (Potter & Haley, 1983). In particular, 2- and 8-azido 
analogues of purine nucleotides have been used as site-di 
rected photoprobes to identify nucleotide-binding proteins in 
crude cell extracts (Owens & Haley, 1987; Atherton et al., 
1985). The 2- and 8-azido nucleotides have also been used to 
map nucleotide-binding domains of purified proteins 
(Khatoon et al., 1989: King et al., 1989; and Dholakia et al., 
1989) and may be used as ligand binding agents. 
Labeling can be carried out by any of the techniques well 
known to those of skill in the art. For instance, ligands can be 
labeled by contacting the ligand with the desired label and a 
chemical oxidizing agent such as sodium hypochlorite, or an 
enzymatic oxidizing agent, such as lactoperoxidase. Simi 
larly, a ligand exchange process could be used. Alternatively, 
direct labeling techniques may be used, e.g., by incubating 
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the label, a reducing agent such as SNC1, a buffer solution 
Such as sodium-potassium phthalate Solution, and the ligand. 
Intermediary functional groups on the ligand could also be 
used, for example, to bind labels to a ligand in the presence of 
diethylenetriaminepentaacetic acid (DTPA) or ethylene 
diaminetetracetic acid (EDTA). 
Other methods are also known in the art for the attachment 
or conjugation of a ligand to its conjugate moiety. Some 
attachment methods involve the use of an organic chelating 
agent Such as diethylenetriaminepentaacetic acid anhydride 
(DTPA): ethylenetriaminetetraacetic acid; N-chloro-p-tolu 
enesulfonamide; and/or tetrachloro-3C-6C.-diphenylgly 
couril-3 attached to the ligand (U.S. Pat. Nos. 4.472,509 and 
4.938,948, each incorporated herein by reference). Ligands 
also may be reacted with an enzyme in the presence of a 
coupling agent such as glutaraldehyde or periodate. Conju 
gates with fluorescein markers can be prepared in the pres 
ence of these coupling agents or by reaction with an isothio 
cyanate. In U.S. Pat. No. 4,938.948, imaging of breast tumors 
is achieved using monoclonal antibodies and the detectable 
imaging moieties are bound to the antibody using linkers such 
as methyl-p-hydroxybenzimidate or N-succinimidyl-3-(4- 
hydroxyphenyl)propionate. 
The ability to specifically label periplasmic expressed pro 
teins with appropriate fluorescent ligands also has applica 
tions other than library screening. Specifically labeling with 
fluorescent ligands and flow cytometry can be used for moni 
toring production during protein manufacturing. While flow 
cytometry has been used previously for the analysis of bac 
terial cells, it has not been used for the specific labeling and 
quantitation of periplasmic proteins. However, a large num 
ber of commercially important proteins including IGF-1 sev 
eral interleukins, enzymes Such as urokinase-type plasmino 
gen activator, antibody fragments, inhibitors (e.g., Bovine 
pancreatic trypsin inhibitor) are expressed in recombinant 
bacteria in a form secreted into the periplasmic space. The 
level of production of such proteins within each cell in a 
culture can be monitored by utilizing an appropriate fluores 
cent ligand and flow cytometric analysis, according to the 
techniques taught by the present invention. 
Generally, monitoring protein expression requires cell 
lysis and detection of the protein by immunological tech 
niques or following chromatographic separation. However, 
ELISA or western blot analysis is time-consuming and does 
not provide information on the distribution of expression 
among a cell population and cannot be used for on-line moni 
toring (Thorstenson et al., 1997: Berrier et al., 2000). In 
contrast, FACS labeling is rapid and simple and can well be 
applied to online monitoring of industrial size fermentations 
of recombinant proteins expressed in Gram-negative bacte 
ria. Similarly, the invention could be used to monitor the 
production of a particular byproduct of a biological reaction. 
This also could be used to measure the relative concentration 
or specific activity of an enzyme expressed in Vivo in a bac 
terium or provided ex vivo. 
Once a ligand-binding protein, such as an antibody, has 
been isolated in accordance with the invention, it may be 
desired to link the molecule to at least one agent to form a 
conjugate to enhance the utility of that molecule. For 
example, in order to increase the efficacy of antibody mol 
ecules as diagnostic ortherapeutic agents, it is conventional to 
link or covalently bind or complex at least one desired mol 
ecule or moiety. Such a molecule or moiety may be, but is not 
limited to, at least one effector or reporter molecule. Effector 
molecules comprise molecules having a desired activity, e.g., 
cytotoxic activity. Non-limiting examples of effector mol 














anti-tumor agents, therapeutic enzymes, radio-labeled nucle 
otides, antiviral agents, chelating agents, cytokines, growth 
factors, and oligo- or poly-nucleotides. By contrast, a reporter 
molecule is defined as any moiety which may be detected 
using an assay. Techniques for labeling Such a molecule are 
known to those of skill in the art and have been described 
herein above. 
Labeled binding proteins such as antibodies which have 
been prepared in accordance with the invention may also then 
be employed, for example, in immunodetection methods for 
binding, purifying, removing, quantifying and/or otherwise 
generally detecting biological components such as protein(s), 
polypeptide(s) or peptide(s). Some immunodetection meth 
ods include enzyme linked immunosorbent assay (ELISA), 
radioimmunoassay (RIA), immunoradiometric assay, fluor 
oimmunoassay, chemiluminescent assay, bioluminescent 
assay, and Western blot to mention a few. The steps of various 
useful immunodetection methods have been described in the 
Scientific literature. Such as, e.g., Doolittle and Ben-Zeev 
(1999); Gulbis and Galand (1993); De Jager et al. (1993), 
each incorporated herein by reference. Such techniques 
include binding assays such as the various types of enzyme 
linked immunosorbent assays (ELISAS) and/or radioimmu 
noassays (RIA) known in the art. 
The ligand-binding molecules, including antibodies, pre 
pared in accordance with the present invention may also, for 
example, in conjunction with both fresh-frozen and/or forma 
lin-fixed, paraffin-embedded tissue blocks prepared for study 
by immunohistochemistry (IHC). The method of preparing 
tissue blocks from these particulate specimens has been Suc 
cessfully used in previous IHC studies of various prognostic 
factors, and/or is well known to those of skill in the art 
(Abbondanzo et al., 1990). 
IV. Automated Screening with Flow Cytometry 
Fluorescence activated cell sorting (FACS) screening or 
other automated flow cytometric techniques may be used for 
the efficient isolation of a bacterial cell comprising a labeled 
ligand bound to a candidate molecule and linked to the outer 
face of the cytoplasmic membrane of the bacteria. Instru 
ments for carrying out flow cytometry are known to those of 
skill in the art and are commercially available to the public. 
Examples of such instruments include FACS Star Plus, FAC 
Scan and FACSort instruments from Becton Dickinson (Fos 
ter City, Calif.) Epics C from Coulter Epics Division (Hi 
aleah, Fla.) and MoFlo from Cytomation (Colorado Springs, 
Colo.). 
Flow cytometric techniques in general involve the separa 
tion of cells or other particles in a liquid sample. Typically, the 
purpose of flow cytometry is to analyze the separated par 
ticles for one or more characteristics thereof, for example, 
presence of a labeled ligand or other molecule. The basis steps 
of flow cytometry involve the direction of a fluid sample 
through an apparatus Such that a liquid stream passes through 
a sensing region. The particles should pass one at a time by the 
sensor and are categorized base on size, refraction, light scat 
tering, opacity, roughness, shape, fluorescence, etc. 
Rapid quantitative analysis of cells proves useful in bio 
medical research and medicine. Apparati permit quantitative 
multiparameter analysis of cellular properties at rates of sev 
eral thousand cells per second. These instruments provide the 
ability to differentiate among cell types. Data are often dis 
played in one-dimensional (histogram) or two-dimensional 
(contour plot, scatter plot) frequency distributions of mea 
sured variables. The partitioning of multiparameter data files 
involves consecutive use of the interactive one- or two-di 
mensional graphics programs. 
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Quantitative analysis of multiparameter flow cytometric 
data for rapid cell detection consists of two stages: cell class 
characterization and sample processing. In general, the pro 
cess of cell class characterization partitions the cell feature 
into cells of interest and not of interest. Then, in sample 
processing, each cell is classified in one of the two categories 
according to the region in which it falls. Analysis of the class 
of cells is very important, as high detection performance may 
be expected only if an appropriate characteristic of the cells is 
obtained. 
Not only is cell analysis performed by flow cytometry, but 
so too is sorting of cells. In U.S. Pat. No. 3,826,364, an 
apparatus is disclosed which physically separates particles, 
Such as functionally different cell types. In this machine, a 
laser provides illumination which is focused on the stream of 
particles by a suitable lens or lens system so that there is 
highly localized scatter from the particles therein. In addition, 
high intensity Source illumination is directed onto the stream 
of particles for the excitation of fluorescent particles in the 
stream. Certain particles in the stream may be selectively 
charged and then separated by deflecting them into desig 
nated receptacles. A classic form of this separation is via 
fluorescent-tagged antibodies, which are used to mark one or 
more cell types for separation. 
Other examples of methods for flow cytometry that could 
include, but are not limited to, those described in U.S. Pat. 
Nos. 4,284,412: 4,989,977; 4,498,766; 5,478,722:4,857,451: 
4,774, 189; 4,767,206; 4,714,682; 5,160,974; and 4,661,913, 
each of the disclosures of which are specifically incorporated 
herein by reference. 
For the present invention, an important aspect of flow 
cytometry is that multiple rounds of screening can be carried 
out sequentially. Cells may be isolated from an initial round 
of sorting and immediately reintroduced into the flow cytom 
eter and Screened again to improve the stringency of the 
screen. Another advantage known to those of skill in the artis 
that nonviable cells can be recovered using flow cytometry. 
Since flow cytometry is essentially a particle sorting technol 
ogy, the ability of a cell to grow or propagate is not necessary. 
Techniques for the recovery of nucleic acids from Such non 
viable cells are well known in the art and may include, for 
example, use oftemplate-dependent amplification techniques 
including PCR. 
V. Nucleic Acid-Based Expression Systems 
Nucleic acid-based expression systems may find use, in 
certain embodiments of the invention, for the expression of 
recombinant proteins. For example, one embodiment of the 
invention involves transformation of Gram negative bacteria 
with the coding sequences of fusion polypeptides comprising 
a candidate antibody or other binding protein having affinity 
for a selected ligand and the expression of such molecules on 
the cytoplasmic membrane of the Gram negative bacteria. In 
other embodiments of the invention, expression of Such cod 
ing sequences may be carried, for example, in eukaryotic host 
cells for the preparation of isolated binding proteins having 
specificity for the target ligand. The isolated protein could 
then be used in one or more therapeutic or diagnostic appli 
cations. 
A. Methods of Nucleic Acid Delivery 
Certain aspects of the invention may comprise delivery of 
nucleic acids to target cells. For example, bacterial host cells 
may be transformed with nucleic acids encoding candidate 
molecules potentially capable binding a target ligand. In par 
ticular embodiments of the invention, it may be desired to 
target the expression to the cytoplasmic membrane of the 













larly find use in the expression of various candidate molecules 
identified as capable of binding a target ligand. 
Suitable methods for nucleic acid delivery for transforma 
tion of a cell are believed to include virtually any method by 
which a nucleic acid (e.g., DNA) can be introduced into Such 
a cell, or even an organelle thereof. Such methods include, but 
are not limited to, direct delivery of DNA such as by injection 
(U.S. Pat. Nos. 5,994,624, 5,981,274, 5,945,100, 5,780,448, 
5,736,524, 5,702,932, 5,656,610, 5,589,466. and 5,580,859, 
each incorporated herein by reference), including microin 
jection (Harlan and Weintraub, 1985; U.S. Pat. No. 5,789, 
215, incorporated herein by reference); by electroporation 
(U.S. Pat. No. 5,384,253, incorporated herein by reference): 
by calcium phosphate precipitation (Graham and VanDer Eb. 
1973; Chen and Okayama, 1987: Rippe et al., 1990); by using 
DEAE-dextran followed by polyethylene glycol (Gopal, 
1985); by direct sonic loading (Fechheimer et al., 1987); by 
liposome mediated transfection (Nicolau and Sene, 1982; 
Fraley et al., 1979; Nicolau et al., 1987; Wong et al., 1980; 
Kaneda et al., 1989: Kato et al., 1991); by microprojectile 
bombardment (PCT Application Nos. WO 94/09699 and 
95/06128: U.S. Pat. Nos. 5,610,042; 5,322,783 5,563,055, 
5,550,318, 5.538,877 and 5,538,880, and each incorporated 
herein by reference); by agitation with silicon carbide fibers 
(Kaeppler et al., 1990; U.S. Pat. Nos. 5,302,523 and 5,464, 
765, each incorporated herein by reference); by Agrobacte 
rium-mediated transformation (U.S. Pat. Nos. 5,591.616 and 
5,563.055, each incorporated herein by reference); or by 
PEG-mediated transformation of protoplasts (Omirulleh et 
al., 1993; U.S. Pat. Nos. 4,684,611 and 4,952,500, each incor 
porated herein by reference); by desiccation/inhibition-me 
diated DNA uptake (Potrykus et al., 1985). Through the appli 
cation of techniques such as these, organelle(s), cell(s), 
tissue(s) or organism(s) may be stably or transiently trans 
formed. 
1. Electroporation 
In certain embodiments of the present invention, a nucleic 
acid is introduced into a cell via electroporation. Electropo 
ration involves the exposure of a suspension of cells and DNA 
to a high-voltage electric discharge. In some variants of this 
method, certain cell wall-degrading enzymes, such as pectin 
degrading enzymes, are employed to render the target recipi 
ent cells more Susceptible to transformation by electropora 
tion than untreated cells (U.S. Pat. No. 5,384,253, 
incorporated herein by reference). Alternatively, recipient 
cells can be made more Susceptible to transformation by 
mechanical wounding. 
2. Calcium Phosphate 
In other embodiments of the present invention, a nucleic 
acid is introduced to the cells using calcium phosphate pre 
cipitation. Human KB cells have been transfected with aden 
ovirus 5 DNA (Graham and Van Der Eb. 1973) using this 
technique. Also in this manner, mouse L(A9), mouse C 127. 
CHO, CV-1, BHK, NIH3T3 and HeLa cells were transfected 
with a neomycin marker gene (Chen and Okayama, 1987), 
and rathepatocytes were transfected with a variety of marker 
genes (Rippe et al., 1990). 
B. Vectors 
Vectors may find use with the current invention, for 
example, in the transformation of a Gram negative bacterium 
with a nucleic acid sequence encoding a candidate polypep 
tide which one wishes to screen for ability to bind a target 
ligand. In one embodiment of the invention, an entire hetero 
geneous “library of nucleic acid sequences encoding target 
polypeptides may be introduced into a population of bacteria, 
thereby allowing screening of the entire library. The term 
“vector” is used to refer to a carrier nucleic acid molecule into 
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which a nucleic acid sequence can be inserted for introduc 
tion into a cell where it can be replicated. A nucleic acid 
sequence can be “exogenous.” or "heterologous', which 
means that it is foreign to the cell into which the vector is 
being introduced or that the sequence is homologous to a 
sequence in the cell but in a position within the host cell 
nucleic acid in which the sequence is ordinarily not found. 
Vectors include plasmids, cosmids, viruses (bacteriophage, 
animal viruses, and plant viruses), and artificial chromo 
Somes (e.g., YACs). One of skill in the art may construct a 
vector through standard recombinant techniques, which are 
described in Maniatis et al., 1988 and Ausubel et al., 1994, 
both of which references are incorporated herein by refer 
CCC. 
The term “expression vector” refers to a vector containing 
a nucleic acid sequence coding for at least part of a gene 
product capable of being transcribed. In some cases, RNA 
molecules are then translated into a protein, polypeptide, or 
peptide. In other cases, these sequences are not translated, for 
example, in the production of antisense molecules or 
ribozymes. Expression vectors can contain a variety of "con 
trol sequences, which refer to nucleic acid sequences neces 
sary for the transcription and possibly translation of an oper 
ably linked coding sequence in a particular host organism. In 
addition to control sequences that govern transcription and 
translation, vectors and expression vectors may contain 
nucleic acid sequences that serve other functions as well and 
are described infra. 
1. Promoters and Enhancers 
A "promoter is a control sequence that is a region of a 
nucleic acid sequence at which initiation and rate of transcrip 
tion are controlled. It may contain genetic elements at which 
regulatory proteins and molecules may bind Such as RNA 
polymerase and other transcription factors. The phrases 
“operatively positioned.” “operatively linked.” “under con 
trol.” and “under transcriptional control’ mean that a pro 
moter is in a correct functional location and/or orientation in 
relation to a nucleic acid sequence to control transcriptional 
initiation and/or expression of that sequence. A promoter may 
or may not be used in conjunction with an "enhancer, which 
refers to a cis-acting regulatory sequence involved in the 
transcriptional activation of a nucleic acid sequence. 
A promoter may be one naturally associated with a gene or 
sequence, as may be obtained by isolating the 5' non-coding 
sequences located upstream of the coding segment and/or 
exon. Such a promoter can be referred to as "endogenous.” 
Similarly, an enhancer may be one naturally associated with 
a nucleic acid sequence, located either downstream or 
upstream of that sequence. Alternatively, certain advantages 
will begained by positioning the coding nucleic acid segment 
under the control of a recombinant or heterologous promoter, 
which refers to a promoter that is not normally associated 
with a nucleic acid sequence in its natural environment. A 
recombinant or heterologous enhancer refers also to an 
enhancer not normally associated with a nucleic acid 
sequence in its natural environment. Such promoters or 
enhancers may include promoters or enhancers of other 
genes, and promoters or enhancers isolated from any other 
prokaryotic, viral, or eukaryotic cell, and promoters or 
enhancers not “naturally occurring, i.e., containing different 
elements of different transcriptional regulatory regions, and/ 
or mutations that alter expression. In addition to producing 
nucleic acid sequences of promoters and enhancers syntheti 
cally, sequences may be produced using recombinant cloning 
and/or nucleic acid amplification technology, including 
PCRTM, in connection with the compositions disclosed herein 













herein by reference). Furthermore, it is contemplated that the 
control sequences that direct transcription and/or expression 
of sequences within non-nuclear organelles Such as mito 
chondria, chloroplasts, and the like, can be employed as well. 
Naturally, it will be important to employ a promoter and/or 
enhancer that effectively directs the expression of the DNA 
segment in the cell type, organelle, and organism chosen for 
expression. One example of Such promoter that may be used 
with the invention is the E. coli arabinose promoter. Those of 
skill in the art of molecular biology generally are familiar 
with the use of promoters, enhancers, and cell type combina 
tions for protein expression, for example, see Sambrook et al. 
(1989), incorporated herein by reference. The promoters 
employed may be constitutive, tissue-specific, inducible, and/ 
or useful under the appropriate conditions to direct high level 
expression of the introduced DNA segment, Such as is advan 
tageous in the large-scale production of recombinant proteins 
and/or peptides. The promoter may be heterologous or endog 
COUS. 
2. Initiation Signals and Internal Ribosome Binding Sites 
A specific initiation signal also may be required for effi 
cient translation of coding sequences. These signals include 
the ATG initiation codon or adjacent sequences. Exogenous 
translational control signals, including the ATG initiation 
codon, may need to be provided. One of ordinary skill in the 
art would readily be capable of determining this and provid 
ing the necessary signals. It is well known that the initiation 
codon must be “in-frame with the reading frame of the 
desired coding sequence to ensure translation of the entire 
insert. The exogenous translational control signals and initia 
tion codons can be either natural or synthetic. The efficiency 
of expression may be enhanced by the inclusion of appropri 
ate transcription enhancer elements. 
3. Multiple Cloning Sites 
Vectors can include a multiple cloning site (MCS), which is 
a nucleic acid region that contains multiple restriction 
enzyme sites, any of which can be used in conjunction with 
standard recombinant technology to digest the vector (see 
Carbonelli et al., 1999, Levenson et al., 1998, and Cocea, 
1997, incorporated herein by reference.) “Restriction enzyme 
digestion” refers to catalytic cleavage of a nucleic acid mol 
ecule with an enzyme that functions only at specific locations 
in a nucleic acid molecule. Many of these restriction enzymes 
are commercially available. Use of Such enzymes is under 
stood by those of skill in the art. Frequently, a vector is 
linearized or fragmented using a restriction enzyme that cuts 
within the MCS to enable exogenous sequences to be ligated 
to the vector. “Ligation” refers to the process of forming 
phosphodiester bonds between two nucleic acid fragments, 
which may or may not be contiguous with each other. Tech 
niques involving restriction enzymes and ligation reactions 
are well known to those of skill in the art of recombinant 
technology. 
4. Termination Signals 
The vectors or constructs prepared in accordance with the 
present invention will generally comprise at least one termi 
nation signal. A “termination signal' or "terminator” is com 
prised of the DNA sequences involved in specific termination 
ofan RNA transcript by an RNA polymerase. Thus, in certain 
embodiments, a termination signal that ends the production of 
an RNA transcript is contemplated. A terminator may be 
necessary in vivo to achieve desirable message levels. 
Terminators contemplated for use in the invention include 
any known terminator of transcription described herein or 
known to one of ordinary skill in the art, including but not 
limited to, for example, rhp dependent or rho independent 
terminators. In certain embodiments, the termination signal 
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may be a lack of transcribable or translatable sequence. Such 
as due to a sequence truncation. 
5. Origins of Replication 
In order to propagate a vector in a host cell, it may contain 
one or more origins of replication sites (often termed “ori'). 
which is a specific nucleic acid sequence at which replication 
is initiated. Alternatively an autonomously replicating 
sequence (ARS) can be employed if the host cell is yeast. 
6. Selectable and Screenable Markers 
In certain embodiments of the invention, cells containing a 
nucleic acid construct of the present invention may be iden 
tified in vitro or in vivo by including a marker in the expres 
sion vector. Such markers would confer an identifiable 
change to the cell permitting easy identification of cells con 
taining the expression vector. Generally, a selectable marker 
is one that confers a property that allows for selection. A 
positive selectable marker is one in which the presence of the 
marker allows for its selection, while a negative selectable 
marker is one in which its presence prevents its selection. An 
example of a positive selectable marker is a drug resistance 
marker. 
Usually the inclusion of a drug selection marker aids in the 
cloning and identification of transformants, for example, 
genes that confer resistance to neomycin, puromycin, hygro 
mycin, DHFR, GPT. Zeocin and histidinol are useful select 
able markers. In addition to markers conferring a phenotype 
that allows for the discrimination of transformants based on 
the implementation of conditions, other types of markers 
including screenable markers such as GFP, whose basis is 
colorimetric analysis, are also contemplated. Alternatively, 
screenable enzymes such as herpes simplex virus thymidine 
kinase (tk) or chloramphenicol acetyltransferase (CAT) may 
be utilized. One of skill in the art would also know how to 
employ immunologic markers, possibly in conjunction with 
FACS analysis. The marker used is not believed to be impor 
tant, so long as it is capable of being expressed simulta 
neously with the nucleic acid encoding a gene product. Fur 
ther examples of selectable and screenable markers are well 
known to one of skill in the art. 
C. Host Cells 
As used herein, the terms “cell,” “cell line, and “cell 
culture' may be used interchangeably. All of these terms also 
include their progeny, which is any and all Subsequent gen 
erations. It is understood that all progeny may not be identical 
due to deliberate or inadvertent mutations. In the context of 
expressing a heterologous nucleic acid sequence, "host cell” 
refers to a prokaryotic cell, and it includes any transformable 
organism that is capable of replicating a vector and/or 
expressing a heterologous gene encoded by a vector. A host 
cell can, and has been, used as a recipient for vectors. A host 
cell may be “transfected' or “transformed, which refers to a 
process by which exogenous nucleic acid is transferred or 
introduced into the host cell. A transformed cell includes the 
primary Subject cell and its progeny. 
In particular embodiments of the invention, a host cell is a 
Gram negative bacterial cell. These bacteria are suited for use 
with the invention in that they posses a periplasmic space 
between the inner and outer membrane and, particularly, the 
aforementioned inner membrane between the periplasm and 
cytoplasm, which is also known as the cytoplasmic mem 
brane. As such, any other cell with Such a periplasmic space 
could be used in accordance with the invention. Examples of 
Gram negative bacteria that may find use with the invention 
may include, but are not limited to, E. coli, Pseudomonas 
aeruginosa, Vibrio cholera, Salmonella typhimurium, Shi 
gella flexneri, Haemophilus influenza, Bordotella pertussi, 













terial cell may be still further defined as bacterial cell which 
has been transformed with the coding sequence of a fusion 
polypeptide comprising a candidate binding polypeptide 
capable of binding a selected ligand. The polypeptide is 
anchored to the outer face of the cytoplasmic membrane, 
facing the periplasmic space, and may comprise an antibody 
coding sequence or another sequence. One means for expres 
sion of the polypeptide is by attaching a leader sequence to the 
polypeptide capable of causing Such directing. 
Numerous prokaryotic cell lines and cultures are available 
for use as a host cell, and they can be obtained through the 
AmericanType Culture Collection (ATCC), which is an orga 
nization that serves as an archive for living cultures and 
genetic materials. An appropriate host can be determined by 
one of skill in the art based on the vector backbone and the 
desired result. A plasmid or cosmid, for example, can be 
introduced into a prokaryote host cell for replication of many 
vectors. Bacterial cells used as host cells for vector replication 
and/or expression include DH5/C., JM109, and KC8, as well 
as a number of commercially available bacterial hosts such as 
SURE(R) Competent Cells and SOLOPACKTM Gold Cells 
(STRATAGENER), La Jolla). Alternatively, bacterial cells 
such as E. coli LE392 could be used as host cells for bacte 
riophage. 
Many host cells from various cell types and organisms are 
available and would be known to one of skill in the art. 
Similarly, a viral vector may be used in conjunction with a 
prokaryotic host cell, particularly one that is permissive for 
replication or expression of the vector. Some vectors may 
employ control sequences that allow it to be replicated and/or 
expressed in both prokaryotic and eukaryotic cells. One of 
skill in the art would further understand the conditions under 
which to incubate all of the above described host cells to 
maintain them and to permit replication of a vector. Also 
understood and known are techniques and conditions that 
would allow large-scale production of vectors, as well as 
production of the nucleic acids encoded by vectors and their 
cognate polypeptides, proteins, or peptides. 
D. Expression Systems 
Numerous expression systems exist that comprise at least a 
part or all of the compositions discussed above. Such systems 
could be used, for example, for the production of a polypep 
tide product identified in accordance with the invention as 
capable of binding a particular ligand. Prokaryote-based sys 
tems can be employed for use with the present invention to 
produce nucleic acid sequences, or their cognate polypep 
tides, proteins and peptides. Many such systems are commer 
cially and widely available. Other examples of expression 
systems comprise of vectors containing a strong prokaryotic 
promoter such as T7, Tac, Trc. BAD, lambda pl. Tetracycline 
or Lac promoters, the pET Expression System and an E. coli 
expression system. 
E. Candidate Binding Proteins and Antibodies 
In certain aspects of the invention, candidate antibodies or 
other recombinant polypeptides, including proteins and short 
peptides potentially capable of binding a target ligand are 
expressed on the cytoplasmic membrane of a host bacterial 
cell. By expression of a heterogeneous population of Such 
antibodies or other binding polypeptides, those antibodies 
having a high affinity for a target ligand may be identified. 
The identified antibodies may then be used in various diag 
nostic or therapeutic applications, as described herein. 
As used herein, the term “antibody' is intended to refer 
broadly to any immunologic binding agent such as IgG, IgM, 
IgA, Ig) and IgE. The term “antibody' is also used to refer to 
any antibody-like molecule that has an antigen binding 
region, and includes antibody fragments such as Fab'. Fab, 
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F(ab'), single domain antibodies (DABs). Fv, sclv (single 
chain FV), and engineering multivalent antibody fragments 
such as dibodies, tribodies and multibodies. The techniques 
for preparing and using various antibody-based constructs 
and fragments are well known in the art. Means for preparing 
and characterizing antibodies are also well known in the art 
(See, e.g., Antibodies: A Laboratory Manual, Cold Spring 
Harbor Laboratory, 1988; incorporated herein by reference). 
Once an antibody having affinity for a target ligand is 
identified, the antibody or ligand binding polypeptide may be 
purified, if desired, using filtration, centrifugation and various 
chromatographic methods such as HPLC or affinity chroma 
tography. Fragments of such polypeptides, including antibod 
ies, can be obtained from the antibodies so produced by 
methods which include digestion with enzymes, such as pep 
sin or papain, and/or by cleavage of disulfide bonds by chemi 
cal reduction. Alternatively, antibody or other polypeptides, 
including protein fragments, encompassed by the present 
invention can be synthesized using an automated peptide 
synthesizer. 
A molecular cloning approach comprises one Suitable 
method for the generation of a heterogeneous population of 
candidate antibodies that may then be screened in accordance 
with the invention for affinity to target ligands. In one 
embodiment of the invention, combinatorial immunoglobulin 
phagemid can be prepared from RNA isolated from the spleen 
of an animal. By immunizing an animal with the ligand to be 
screened, the assay may be targeted to the particular antigen. 
The advantages of this approach over conventional tech 
niques are that approximately 10 times as many antibodies 
can be produced and screened in a single round, and that new 
specificities are generated by H and L chain combination 
which further increases the chance of finding appropriate 
antibodies. 
VI. Manipulation and Detection of Nucleic Acids 
In certain embodiments of the invention, it may be desired 
to employ one or more techniques for the manipulation, iso 
lation and/or detection of nucleic acids. Such techniques may 
include, for example, the preparation of vectors for transfor 
mation of host cells as well as methods for cloning selected 
nucleic acid segments from a transgenic cell. Methodology 
for carrying out such manipulations will be well known to 
those of skill in the art in light of the instant disclosure. 
Nucleic acids used as a template for amplification may be 
isolated from cells, tissues or other samples according to 
standard methodologies (Sambrook et al., 1989). In certain 
embodiments, analysis may be performed on whole cell or 
tissue homogenates or biological fluid samples without Sub 
stantial purification of the template nucleic acid. The nucleic 
acid may be genomic DNA or fractionated or whole cell 
RNA. Where RNA is used, it may be desired to first convert 
the RNA to a complementary DNA. 
The term “primer as used herein, is meant to encompass 
any nucleic acid that is capable of priming the synthesis of a 
nascent nucleic acid in a template-dependent process. Typi 
cally, primers are oligonucleotides from ten to twenty and/or 
thirty base pairs in length, but longer sequences can be 
employed. Primers may be provided in double-stranded and/ 
or single-stranded form, although the single-stranded form is 
preferred. 
Pairs of primers designed to selectively hybridize to 
nucleic acids corresponding to a selected nucleic acid 
sequence are contacted with the template nucleic acid under 
conditions that permit selective hybridization. Depending 
upon the desired application, high Stringency hybridization 
conditions may be selected that will only allow hybridization 













ers. In other embodiments, hybridization may occur under 
reduced stringency to allow for amplification of nucleic acids 
contain one or more mismatches with the primer sequences. 
Once hybridized, the template-primer complex is contacted 
with one or more enzymes that facilitate template-dependent 
nucleic acid synthesis. Multiple rounds of amplification, also 
referred to as “cycles.” are conducted until a sufficient amount 
of amplification product is produced. 
The amplification product may be detected or quantified. In 
certain applications, the detection may be performed by 
visual means. Alternatively, the detection may involve indi 
rect identification of the product via chemiluminescence, 
radioactive Scintigraphy of incorporated. radiolabel or fluo 
rescent label or even via a system using electrical and/or 
thermal impulse signals (Affymax technology: Bellus, 1994). 
A number of template dependent processes are available 
to amplify the oligonucleotide sequences present in a given 
template sample. One of the best known amplification meth 
ods is the polymerase chain reaction (referred to as PCRTM) 
which is described in detail in U.S. Pat. Nos. 4,683, 195, 
4,683.202 and 4,800,159, and in Innis et al., 1988, each of 
which is incorporated herein by reference in their entirety. 
A reverse transcriptase PCRTM amplification procedure 
may be performed to quantify the amount of mRNA ampli 
fied. Methods of reverse transcribing RNA into cDNA are 
well known (see Sambrook et al., 1989). Alternative methods 
for reverse transcription utilize thermostable DNA poly 
merases. These methods are described in WO 90/07641. 
Polymerase chain reaction methodologies are well known in 
the art. Representative methods of RT-PCR are described in 
U.S. Pat. No. 5,882,864. 
Another method for amplification is ligase chain reaction 
(“LCR), disclosed in European Application 320308, incor 
porated herein by reference in its entirety. U.S. Pat. No. 4,883, 
750 describes a method similar to LCR for binding probe 
pairs to a target sequence. A method based on PCRTM and 
oligonucleotide ligase assay (OLA), disclosed in U.S. Pat. 
No. 5,912,148, may also be used. 
Alternative methods for amplification of target nucleic acid 
sequences that may be used in the practice of the present 
invention are disclosed in U.S. Pat. Nos. 5,843,650, 5,846, 
709, 5,846,783, 5,849,546, 5,849,497, 5,849,547, 5,858,652, 
5,866,366, 5,916,776, 5,922,574, 5,928,905, 5,928,906, 
5,932,451, 5,935,825, 5,939,291 and 5,942,391, GB Appli 
cation No. 2 202 328, and in PCT Application No. PCT/ 
US89/01025, each of which is incorporated herein by refer 
ence in its entirety. 
Qbeta Replicase, described in PCT Application No. PCT/ 
US87/00880, may also be used as an amplification method in 
the present invention. In this method, a replicative sequence 
of RNA that has a region complementary to that of a target is 
added to a sample in the presence of an RNA polymerase. The 
polymerase will copy the replicative sequence which may 
then be detected. 
An isothermal amplification method, in which restriction 
endonucleases and ligases are used to achieve the amplifica 
tion of target molecules that contain nucleotide 5'-alpha 
thio-triphosphates in one strand of a restriction site may also 
be useful in the amplification of nucleic acids in the present 
invention (Walker et al., 1992). Strand Displacement Ampli 
fication (SDA), disclosed in U.S. Pat. No. 5,916,779, is 
another method of carrying out isothermal amplification of 
nucleic acids which involves multiple rounds of strand dis 
placement and synthesis, i.e., nick translation. 
Other nucleic acid amplification procedures include tran 
Scription-based amplification systems (TAS), including 
nucleic acid sequence based amplification (NASBA) and 3SR 
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(Kwoh et al., 1989; Gingeras et al., PCT Application WO 
88/103 15, incorporated herein by reference in their entirety). 
European Application No. 329 822 disclose a nucleic acid 
amplification process involving cyclically synthesizing 
single-stranded RNA (“ssRNA), ssDNA, and double- 5 
stranded DNA (dsDNA), which may be used in accordance 
with the present invention. 
PCT Application WO 89/06700 (incorporated herein by 
reference in its entirety) discloses a nucleic acid sequence 
amplification scheme based on the hybridization of a pro 
moter region/primer sequence to a target single-stranded 
DNA (“ssDNA) followed by transcription of many RNA 
copies of the sequence. This scheme is not cyclic, i.e., new 
templates are not produced from the resultant RNA tran 
scripts. Other amplification methods include “race' and 




The following examples are included to demonstrate pre- 20 
ferred embodiments of the invention. It should be appreciated 
by those of skill in the art that the techniques disclosed in the 
examples which follow represent techniques discovered by 
the inventor to function well in the practice of the invention, 
and thus can be considered to constitute preferred modes for 
its practice. However, those of skill in the art should, in light 
of the present disclosure, appreciate that many changes can be 
made in the specific embodiments which are disclosed and 
still obtain a like or similar result without departing from the 




Use of Anchored Periplasmic Expression to Isolate 
Antibodies With Over a 120-Fold Improvement in 
Affinity for the Bacillus anthracis Protective Antigen 
35 
The screening of large libraries requires a physical link 
between a gene, the protein it encodes, and the desired func 
tion. Such a link can be established using a variety of in vivo 
display technologies that have proven invaluable for mecha 
nistic Studies, for biotechnological purposes and for proteom 
ics research (Hoess, 2001; Hayhurst and Georgiou, 2001; 
Wittrup, 2000). 
APEX is an alternative approach that allows screening by 
flow cytometry (FC). FC combines high throughput with 
real-time, quantitative, multi-parameter analysis of each 
library member. With sorting rates on the order of more than 
400 million cells per hour, commercial FC machines can be 
employed to screen libraries of the size accessible within the 
constraints of microbial transformation efficiencies. Further 
more, multi-parameter FC can provide valuable information 
regarding the function of each and every clone in the library in 
real time, thus helping to guide the library construction pro 
cess and optimize sorting conditions (Boder and Wittrup, 55 
2000: Daugherty et al., 2000). 
Bacterial and yeast protein display in combination with FC 
has been employed for the engineering of high affinity anti 
bodies to a variety of ligands (Daugherty et al., 1999: Boder 
et al., 2000). However, the requirement for the display of 60 
proteins on cell Surfaces imposes a number of biological 
constraints that can impact library screening applications. 
Processes Such as the unfolded protein response in eucaryotes 
or the stringency of protein sorting to the outer membrane of 
Gram-negative bacteria limit the diversity of the polypeptides 65 
that are actually compatible with Surface display (Sagt et al., 





faces are chemically complex structures whose macromo 
lecular composition can interfere with protein:ligand recog 
nition. This problem is particularly manifest in Gram 
negative bacteria because the presence of 
lipopolysaccharides on the outer membrane presents a steric 
barrier to protein:ligand recognition, a fact that likely con 
tributed to the evolution of specialized appendages, such as 
pili or fimbriae (Hultgren et al., 1996). 
APEX overcomes the biological constraints and antigen 
access limitations of previous display strategies, enabling the 
efficient isolation of antibodies to virtually any size antigen. 
In APEX, proteins are tethered to the external (periplasmic) 
side of the E. coli cytoplasmic membrane as either N- or 
C-terminal fusions, thus eliminating biological constraints 
associated with the display of proteins on the cell surface. 
Following chemical/enzymatic permeabilization of the bac 
terial outer membrane, E. coli cells expressing anchored scEv 
antibodies can be specifically labeled with fluorescent anti 
gens, of at least 240 kDa, and analyzed by FC. By using 
APEX the inventors have demonstrated the efficient isolation 
of antibodies with markedly improved ligand affinities, 
including an antibody fragment to the protective antigen of 
Bacillus anthracis with an affinity that was increased over 
120-fold. 
A. Anchored Periplasmic Expression and Detection of 
Ligand Binding 
For screening applications, an ideal expression system 
should minimize cell toxicity or growth abnormalities that 
can arise from the synthesis of heterologous polypeptides 
(Daugherty et al., 2000). Use of APEX avoids the complica 
tions that are associated with transmembrane protein fusions 
(Miroux and Walker, 1996; Mingarro et al., 1997). Unlike 
membrane proteins, bacterial lipoproteins are not known to 
require the SRP or YidC pathways for membrane anchoring 
(Samuelson et al., 2000). Lipoproteins are secreted across the 
membrane via the Sec pathway and once in the periplasm, a 
diacylglyceride group is attached through a thioether bond to 
a cysteine residue on the C-terminal side of the signal 
sequence. The signal peptide is then cleaved by signal pepti 
dase II, the protein is fatty acylated at the modified cysteine 
residue, and finally the lipophilic fatty acid inserts into the 
membrane, thereby anchoring the protein (Pugsley, 1993; 
Seydel et al., 1999: Yajushi et al., 2000). 
A sequence encoding the leader peptide and first six amino 
acids of the mature NIpA (containing the putative fatty acy 
lation and inner membrane targeting sites) was employed for 
anchoring Schvantibodies to the periplasmic face of the inner 
membrane. NlpA is a non-essential E. coli lipoprotein that 
exclusively localizes to the inner membrane (Yu et al., 1986: 
Yamaguchi et al., 1988). Of particular note is the aspartate 
residue adjacent to the fatty acylated cysteine residue that is 
thought to be a consensus residue for inner membrane target 
ing (Yamaguchi et al., 1988). NlpA fusions to the 26-10 
anti-digoxin/digoxigenin (Dig) Sclv and to the anti-B. 
anthracis protective antigen (PA) 14B7 schv were con 
structed and expressed from a lac promoter in E. coli. Fol 
lowing induction of the NlpA-schv synthesis using IPTG, 
the cells were incubated with EDTA and lysozyme to disrupt 
the outer membrane and the cell wall. The permeabilized cells 
were mixed with the respective antigens conjugated to the 
fluorescent dye BODIPYTM (200 nM) and the cell fluores 
cence was determined by flow cytometry. Treated cells 
expressing the NlpA-14B7 scFv and the NlpA-Dig schv 
exhibited an approximate 9-fold and 16-fold higher mean 
fluorescence intensity, respectively, compared to controls 
(FIG. 2A). Only background fluorescence was detected when 
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the cells were mixed with unrelated fluorescent antigen, indi 
cating negligible background binding under the conditions of 
the study. 
To further evaluate the ability of antibody fragments 
anchored on the cytoplasmic membrane to bind bulky anti 
gens, the inventors examined the ability of the NlpA-Dig 
ScFV to recognize digoxigenin conjugated to the 240 kDa 
fluorescent protein phycoerythrin (PE). The conjugate was 
mixed with cells expressing NlpA-Dig scFv and treated 
with EDTA-lysozyme. A high cell fluorescence was observed 
indicating binding of digoxigenin-PE conjugate by the mem 
braneanchored antibody (FIG.2B). Overall, the accumulated 
data demonstrated that in cells treated with Tris-EDTA 
lysozyme, ScPVs anchored on the cytoplasmic membrane can 
readily bind to ligands ranging from Small molecules to pro 
teins of at least up to 240 kDa in molecular weight. Impor 
tantly, labeling with digoxigenin-PE followed by one round 
of flow cytometry resulted in an over 500-fold enrichment of 
bacteria expressing NlpA-Dig Schv from cells expressing a 
similar fusion with a Schv having unrelated antigen specific 
ity. 
B. Library Screening by APEX 
A library of 1x107 members was constructed by error 
prone PCR of the gene for the anti-PA 144B7 schv and was 
fused to the NlpA membrane anchoring sequence. DNA 
sequencing of 12 library clones selected at random revealed 
an average of 2% nucleotide Substitutions per gene. Follow 
ing induction of Nlp A-14B7 mutant schv synthesis with 
IPTG, the cells were treated with Tris-EDTA-lysozyme, 
washed, and labeled with 200 nM PA-BODIPYTM. Inner 
membrane integrity was monitored by staining with pro 
pidium iodide (PI). A total of 2x10 bacteria were sorted 
using an ultra-high throughput Cytomation Inc. MoFlo drop 
let deflection flow cytometer selectively gating for low PI 
fluorescence (630 nm emission) and high BODIPYTM fluo 
rescence. Approximately 5% of the cells sorted with the high 
est 530 nm fluorescence (FL1) were collected, immediately 
restained with PI alone and resorted as above. Since no anti 
gen was added during this second sorting cycle, only cells 
expressing antibodies that have slow dissociation kinetics 
remain fluorescent. The plating efficiency of this population 
was low, presumably due to a combination of potential Schv 
toxicity (Somerville et al., 1994; Hayhurst and Harris, 1999), 
Tris-EDTA-lysozyme treatment and exposure to the high 
shear flow cytometry environment. Therefore, to avoid loss of 
potentially high affinity clones, DNA encoding schvs was 
rescued by PCRT amplification of the approximately 1x10' 
fluorescent events recovered by sorting. It should be noted 
that the conditions used for PCRTM amplification result in the 
quantitative release of cellular DNA from the cells which 
have partially hydrolyzed cell walls due to the Tris-EDTA 
lysozyme treatment during labeling. Following 30 rounds of 
PCRTM amplification, the DNA was ligated into paPEx1 and 
transformed into fresh E. coli. A second round of sorting was 
performed exactly as above, except that in this case only the 
most fluorescent 2% of the population was collected and then 
immediately resorted to yield approximately 5,000 fluores 
cent eVentS. 
The scFv DNA from the second round was amplified by 
PCRT and ligated into pMoPac16 (Hayhurst et al., 2003) for 
expression of the antibody fragments in soluble form in the 
ScAb format. A scAb antibody fragment is comprised of an 
ScFv in which the light chain is fused to a human kappa 
constant region. This antibody fragment format exhibits bet 
ter periplasmic solubility compared to schvs (Maynard et al., 
2002; Hayhurst, 2000). 20 clones in the scAb format were 













induction with IPTG, periplasmic proteins were isolated and 
the scAb proteins were rank-ordered with respect to their 
relative antigen dissociation kinetics, using Surface plasmon 
resonance (SPR) analysis. 11 of the 20 clones exhibited 
slower antigen dissociation kinetics compared to the 14B7 
parental antibody. The 3 scAbs with the slowest antigen dis 
Sociation kinetics were produced in large scale and purified 
by Nichromatography followed by gel filtration FPLC. Inter 
estingly, all the library-selected clones exhibited excellent 
expression characteristics and resulted in yields of between 
4-8 mg of purified protein per L in shake flask culture. 
Detailed BIACore analysis indicated that all 3 clones exhibit 
a substantially lower K, for PA compared to the parental 
14B7 antibody (FIGS.3A and 3B). The improved Kresulted 
primarily from slower antigen dissociation, (i.e. slower k). 
The highest affinity clone, M18, exhibited K, of 35 pM, with 
a kg of 4.2x10 M' sec' which corresponds to a M18-PA 
half life of 6.6 hours. This represents over 120-fold affinity 
improvement compared to the parental antibody 14B7 
(K-4.3 nM as determined by BIACore 3000). The muta 
tions identified are given in FIG. 3B and a schematic showing 
the conformation of the 1H, M5, M6 and M18 antibodies is 
given in FIG. 5. The mutations for M5 were as follows: in the 
light chain, Q38R, Q55L, S56P.T74A, Q78L and in the heavy 
chain, K62R. For M6, the mutations were as follows: S22G, 
L33S, Q55L, S56P, Q78L AND L94 P. and in the heavy chain, 
S7P. K19R, S30N, T68I and M8OL. For M18, the mutations 
were as follows: in the light chain, I21V. L46F, S56P. S76N, 
Q78L and L94P and in the heavy chain, S30N, T57S, K64E 
and T68. FIG. 6 shows an alignment of 14B7 schv (SEQ ID 
NO:21) and M18 scFv (SEQID NO:23) sequences indicating 
the variable heavy and variable light chains and mutations 
made. The nucleic acids encoding these sequences are given 
in SEQID NO:20 and SEQID NO:22, respectively. 
The fluorescence intensity of Tris-EDTA-lysozyme per 
meabilized cells expressing NlpA fusions to the mutant anti 
bodies varied in proportion to the antigen binding affinity. 
(FIG. 3C) For example, cells expressing the NlpA-M18 
schv protein displayed a mean fluorescence of 250 whereas 
the cells that expressed the parental 14B7 schv exhibited a 
mean fluorescence of 30, compared to a background fluores 
cence of around 5 (FIG. 3B). Antibodies with intermediate 
affinities displayed intermediate fluorescence intensities in 
line with their relative affinity rank. The ability to resolve 
cells expressing antibodies exhibiting dissociation constants 
as low as 35 pM provides a reasonable explanation for why 
three unique very high affinity variants could be isolated and 
is indicative of the fine resolution that can be obtained with 
flow cytometric analysis. 
The 3 clones analyzed in detail, M5, M6 and M18, con 
tained 7, 12, and 11 amino acid Substitutions, respectively. In 
earlier studies using phage display (Maynard et al., 2002; 
U.S. patent application Ser. No. 10/288.269, filed Nov. 5, 
2002, the disclosure of which is incorporated herein by ref 
erence in the entirety), the inventors isolated a variant of the 
14B7 Schv by three cycles, each consisting of 1) mutagenic 
error prone PCRTM.2) five rounds of phage panning and 3) 
DNA shuffling of the post-panning clones. The best clone 
isolated in that study, 1H, contained Q55L and S56P substi 
tutions and exhibited a K, of 150 pM (as determined by a 
BIACore3000). These two mutations likely increase the 
hydrophobicity of the binding pocket adding to the mounting 
evidence that an increase in hydrophobic interactions is a 
dominant effect in antibody affinity maturation (Li et al., 
2003). The same amino acid substitutions are also found in 
the M5 and M6 clones isolated by APEX. However, the pres 
ence of the additional mutations in these two clones conferred 
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a further increase in affinity. It is noteworthy that the M5, M6 
and M18 were isolated following a single round of asexual 
PCRTM yet they all had higher affinity relative to the best 
antibody that could be isolated by phage display, even fol 
lowing multiple rounds of sexual mutagenesis and selection. 
M18, the highest affinity clone isolated by APEX, con 
tained the S56P mutation but lacked the Q55L substitution 
found in 1H, M5, and M6. When the QSSL substitution was 
introduced into M18 by site specific mutagenesis, the result 
ant ScAb exhibited a further improvement in antigenbinding 
(Ki-21 pM) with a k, of 1.1x10'M' sec' and a kar of 
2.4x10 sec', corresponding to a complex half life of 11.6 
hours. However, the introduction of this mutation reduced the 
yield of purified protein more than 5-fold to 1.2 mg/L in shake 
flask culture. The modified M18 sequence is given in SEQID 
NO:25 and the nucleic acid encoding this sequence is given in 
SEQID NO:24. 
C. APEX of Phage Displayed scFv Antibodies 
Numerous antibody fragments to important therapeutic 
and diagnostic targets have been isolated from repertoire 
libraries screened by phage display. It is desirable to develop 
a means for rapid antigen binding analysis and affinity matu 
ration of such antibodies without the need for time consuming 
Subcloning steps. Antibodies are most commonly displayed 
on filamentous phage via fusion to the N-terminus of the 
phage gene 3 minor coat protein (g3p) (Barbas et al., 1991). 
During phage morphogenesis, g3p becomes transiently 
attached to the inner membrane via its extreme C-terminus, 
before it can be incorporated onto the growing virion (Boeke 
and Model, 1982). The antibody fragments are thus both 
anchored and displayed in the periplasmic compartment. 
Therefore, the inventors evaluated whether g3p fusion pro 
teins can be exploited for antibody library Screening purposes 
using the APEX format. The high affinity anti-PA M18 schv 
discussed above, the anti-digoxin/digoxigenin 26-10 schv, 
and an anti-methamphetamine schv (Meth) were cloned in 
frame to the N-terminus of g3p downstream from a lac pro 
moter in phagemidp AK200, which is widely used for phage 
display purposes and utilizes a short variant of gene III for 
g3p display (Krebber et al., 1997). Following induction with 
IPTG, cells expressing scFv-g3p fusions were permeabilized 
by Tris-EDTA-lysozyme and labeled with the respective fluo 
rescent antigens (FIG. 4). High fluorescence was obtained for 
all three scFVs only when incubated with their respective 
antigens. Significantly, the mean fluorescence intensity of the 
sch vs fused to the N-terminus of g3p was comparable to that 
obtained by fusion to the C-terminus of the Nlp A anchor. The 
results in FIG. 4 demonstrate that: (i) large soluble domains 
can be tethered N-terminally to a membrane anchor; (ii) anti 
body fragments cloned into phagemids for display on fila 
mentous phage can be readily analyzed by flow cytometry 
using the APEX format, and (iii) schv antibodies can be 
anchored on the cytoplasmic membrane either as N- or C-ter 
minal fusions without loss of antigen binding. 
Example 2 
Discussion 
The inventors have developed a allowing efficient selection 
of high affinity ligand-binding proteins, and particularly Schv 
antibodies, from combinatorial libraries. In one aspect, APEX 
is based on the anchoring of proteins to the outer side of the 
inner membrane, followed by disruption of the outer mem 
brane prior to incubation with fluorescently labeled antigen 
and FC Sorting. This strategy offers several advantages over 













approaches: 1) by utilizing a fatty acylated anchor to retain 
the protein in the inner membrane, a fusion as short as 6 amino 
acids is all that was required for the Successful display, poten 
tially decreasing deleterious effects that larger fusions may 
impose; 2) the inner membrane lacks molecules such as LPS 
or other complex carbohydrates that can sterically interfere 
with large antigen binding to displayed antibody fragments; 
3) the fusion must only traverse one membrane before it is 
displayed; 4) both N- and C-terminal fusion strategies can be 
employed; and 5) APEX can be used directly for proteins 
expressed from popular phage display vectors. This latter 
point is particularly important because it enables hybrid 
library screening strategies, in which clones from a phage 
panning experiment can be quantitatively analyzed or Sorted 
further by flow cytometry without the need for any subclon 
ing steps. 
APEX can be employed for the detection of antigens rang 
ing from Small molecules (e.g. digoxigenin and methamphet 
amine <1 kDa) to phycoerythrin conjugates (240 kDa). In 
fact, the phycoerythrin conjugate employed in FIG. 1B is not 
meant to define an upper limit for antigen detection, as it is 
contemplated that larger proteins may be used as well. 
In the example, genes encoding SchvS that bind the fluo 
rescently labeled antigen, were rescued from the sorted cells 
by PCRTM. An advantage of this approach is that it enables the 
isolation of clones that are no longer viable due to the com 
bination of potential schv toxicity, Tris-EDTA-lysozyme dis 
ruption, and FC shear forces. In this way, diversity of isolated 
clones is maximized. Yet another advantage of PCRTM rescue 
is that the amplification of DNA from pooled cells can be 
carried out under mutagenic conditions prior to Subcloning. 
Thus, following each round of selection random mutations 
can be introduced into the isolated genes, simplifying further 
rounds of directed evolution (Hanes and Pluckthun, 1997). 
Further, PCRTM conditions that favor template switching 
among the protein encoding genes in the pool may be 
employed during the amplification step to allow recombina 
tion among the selected clones. It is likely that PCRTM rescue 
would be advantageous in other library screening formats as 
well. 
An important issue with any library screening technology 
is the ability to express isolated clones at a high level. Existing 
display formats involve fusion to large anchoring sequences 
which can influence the expression characteristics of the dis 
played proteins. For this reason, ScFVs that display well may 
not necessarily be amenable to high expression in soluble 
form as non-fusion proteins (Hayhurst et al., 2003). In con 
trast, the short (6 amino acid) tail that may be used for N-ter 
minal tethering of proteins onto the cytoplasmic membrane in 
the current invention is unlikely to affect the expression char 
acteristics of the fusion. Consistent with this hypothesis, all 
three affinity enhanced clones to the anthrax PA toxin isolated 
by APEX exhibited excellent soluble expression characteris 
tics despite having numerous amino acid Substitutions. Simi 
larly, well-expressing clones have been obtained in the affin 
ity maturation of a methamphetamine antibody, suggesting 
that the isolation of clones that can readily be produced in 
soluble form in bacteria at a large Scale might be an intrinsic 
feature of selections with the invention. 
In this example, the inventors employed APEX for affinity 
maturation purposes and have engineered scFVS to the B. 
anthracis protective antigen exhibiting K values as low as 21 
pM. The sclv binding site exhibiting the highest affinity for 
PA has been humanized, converted to full length IgG and its 
neutralizing potential to anthrax intoxication is being evalu 
ated in preclinical Studies. In addition to affinity maturation, 
APEX can be exploited for several other protein engineering 
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applications including the analysis of membrane protein 
topology, whereby a Schvantibody anchored in a periplasmic 
loop is able to bind fluorescent antigen and serves as a fluo 
rescent reporter, and also, the selection of enzyme variants 
with enhanced function. Notably, APEX can be readily 
adapted to enzyme library Sorting, as the cell envelope pro 
vides sites for retention of enzymatic catalytic products, 
thereby enabling selection based directly on catalytic turn 
over (Olsen et al., 2000). The inventors are also evaluating the 
utilization of APEX for the screening of ligands to membrane 
proteins. In conclusion, it has been demonstrated that 
anchored periplasmic expression has the potential to facilitate 
combinatorial library screening and other protein engineering 
applications. 
Example 3 
Recombinant DNA Techniques 
The leader peptide and first six amino acids of the mature 
N1 p.A protein flanked by Ndel and Sfil sites was amplified by 
whole cell PCR of XL1-Blue (Stratagene, CA) using primers 
BRHHO8 5'-GAAGGAGATATACATATGAAACTGACAA 
CACATCATCTA-3' (SEQ ID NO:6) and BRHH09 
5'-CTGGGCCATGGCCGGCTGGGCCTCGCT 
GCTACTCTGGTCGCAACC-3' (SEQID NO:7). The result 
ing N1 p.A fragment was used to replace the pe1B leader 
sequence of pMoPac 1 (Hayhurst et al., 2003) via Ndel and 
Sfil to generate p APEX 1. scFv specific for digoxin (Chen et 
al., 1999), Bacillus anthracis protective antigen PA (Maynard 
et al., 2002) and methamphetamine were inserted down 
stream of the N1 p.A fragment in paPEx 1 via the non-com 
patible Sfil sites. Corresponding g3p fusions of the sclv were 
made by cloning the same genes into phage display vector 
pAK200 (Krebber et al., 1997). 
Example 4 
Growth Conditions 
E. coli ABLE CTM (Stratagene) was the host strain used 
throughout. E. coli transformed with the pAPEx1 or pAK°00 
derivatives were inoculated in terrific broth (TB) supple 
mented with 2% glucose and chloramphenicol at 30 ug/ml to 
an OD600 of 0.1. Cell growth and induction were performed 
as described previously (Chen et al., 2001). Following induc 
tion, the cellular outer membrane was permeabilized as 
described (Neu and Heppel, 1965). Briefly, cells (equivalent 
to approx 1 ml of 20 OD600) were pelleted and resuspended 
in 350 ul of ice-cold solution of 0.75M sucrose, 0.1M Tris 
HCl pH8.0, 100 ug/ml hen egg lysozyme. 700 ul of ice-cold 
1 mM EDTA was gently added and the suspension left on ice 
for 10 min. 50 it of 0.5M MgCl, was added and the mix left 
on ice for a further 10 min. The resulting cells were gently 
pelleted and resuspended in phosphate buffered saline (1x 
PBS) with 200 nM probe at room temperature for 45 min, 
before evaluation by FC. 
Example 5 
Fluorescent Probe 
The synthesis of digoxigenin-BODIPY has been described 
previously (Daugherty et al., 1999). Methamphetamine-fluo 
rescein conjugate was a gift from Roche Diagnostics. Purified 
PA protein kindly provided by S. LepplaNIH, was conjugated 













D-2184 according to the manufacturers instructions. Uncon 
jugated BODIPYTM was removed by dialysis. 
To synthesize digoxigenin-phycoerythrin, R-phycoeryth 
rin and 3-amino-3-dioxydigxigenin hemisuccinamide, Suc 
cinimidyl ester (Molecular Probes) were conjugated at a 1 to 
5 molar ratio according to the manufacturers instructions. 
Free digoxigenin was removed by dialysis in excess PBS. 
Example 6 
Affinity Maturation of scFv Libraries with FC 
Libraries were made from the 14B7 parental scFv using 
error prone PCR using standard techniques (Fromant et al., 
1995) and cloned into the p APEX1 expression vector. Upon 
transformation, induction and labeling the cells were then 
stained with propidium iodide (PI emission 617 nm) to moni 
tor inner membrane integrity. Cells were analyzed on a 
MoFlo (Cytomation) droplet deflection flow cytometer using 
488 nm Argon laser for excitation. Cells were selected based 
on improved fluorescence in the Fluorescein/Bodipy FL 
emission spectrum detecting through a 530/40 band pass filter 
and for the absence of labeling in PI emission detecting 
through a 630/40 band pass filter. 
E. coli captured after the first sort were immediately 
resorted through the flow cytometer. Subsequently, the schv 
genes in the sorted cell suspension were amplified by PCRTM. 
Once amplified, the mutant scFV genes were then recloned 
into pAPEX1 vector, retransformed into cells and then grown 
overnight on agar plates at 30°C. The resulting clones were 
Subjected to a second round of sorting plus resorting as above, 
before scFv genes were subcloned into pMoPac 16 (Hayhurst 
et al., 2003) for expression of scAb protein. 
Example 7 
Surface Plasmon Resonance Analysis 
Monomeric scAb proteins were purified by IMAC/size 
exclusion FPLC as described previously (Hayhurst et al., 
2003). Affinity measurements were obtained via SPR using a 
BIACore3000 instrument. Approximately 500RUs of PA was 
coupled to a CM5 chip using EDC/NHS chemistry. BSA was 
similarly coupled and used for in line subtraction. Kinetic 
analysis was performed at 25°C. in BIA HBS-EP buffer at a 
flow rate 100 ul/min. Five two fold dilutions of each antibody 
beginning at 20 nM were analyzed in triplicate. 
Example 8 
Maximizing the Fluorescence Signal 
The fluorescence intensity of cells expressing Schv anti 
bodies in Soluble form in the periplasm was strongly depen 
dent on the E. coli strain used and on the growth conditions. 
With a 26-10 antibody, the maximum fluorescence intensity 
was obtained when the cells were grown at 25°C. Growth at 
Sub-physiological temperature has several beneficial effects. 
Expression of schvat low temperature (i.e., 25°C.) facilitates 
the proper folding of the scFv both directly, by slowing the 
folding pathway and indirectly by decreasing plasmid copy 
number to reduce expression load. Indeed, direct expression 
of sclv at 37° C. generally yields little or no soluble protein 
(for example see Gough et al., 1999). Outer membrane com 
position is also altered at non-physiological temperatures 
resulting in increased permeability (Martinez et al., 1999). 
Rather dramatic differences among various E. coli strains 
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were noticed. Among several strains tested, the highest fluo 
rescence intensities were obtained in ABLETMC. A prelimi 
nary analysis of protein expression and outer membrane pro 
tein profile in this strain indicated that the higher fluorescent 
signal was not due to the pcnB mutation which reduces the 
copy number of ColE1 origin plasmids but rather, due to 
differences in cell envelope protein composition. In fact, the 
stronger staining of ABLETMC was not related to a higher 
level of protein expression relative to other strains as deduced 
by ELISA and Western blotting. 
Fluorescent labeling under hyperosmotic conditions, 
resulted in significantly greater fluorescence. A 5-7 fold 
increase in fluorescence was obtained when the cells were 
incubated in 5x PBS during labeling (a mean FL1 >150 com 
pared to 20-30 for cells incubated in regular PBS). However, 
the increased signal came at a cost, as cell viability decreased 
considerably. Such a decrease in viability may be undesirable 
when screening highly diverse libraries of proteins, whose 
expression may already have a deleterious effect on the host 
cell. Similarly, co-infection with filamentous phages Such as 
M13KO7 induces the phage shock response, which among 
other things, results in an increase in outer membrane perme 
ability. M13 KO7 infection resulted in a 3-fold increase in the 
mean fluorescence of the population. However, as with hyper 
osmotic shock the viability of the culture, as determined by 
propidium iodide staining was somewhat decreased. 
Labeling of the cells with fluorescent ligand followed by 
incubation with a large excess of free ligand results in a 
time-dependent decrease in the mean fluorescence intensity. 
The rate of the fluorescence decay reflects the dissociation 
rate of the antibody-antigen complex (Daugherty et al., 
2000). For digoxin the rate of fluorescence decay was found 
to be about 3-4 times slower compared to the dissociation rate 
measured with the purified antibody using BIACORE. The 
lower rate of fluorescence decay compared to the dissociation 
rate of the antibody/antigen complex in vitro stems from 
several effects including the collision frequency between 
ligands and cells, the concentration of antibody in the peri 
plasm and, of course, the rate of diffusion through the outer 
membrane (see Martinez et al., (1996) for an analysis of 
kinetics in the periplasmic space). As may be expected, the 
ratio of the rate offluorescence decay in the periplasm relative 
to the in vitro determined krate is antigen dependent. 
Example 9 
Increased Cell Permeability at Sub-Optimum 
Temperature 
The fluorescence intensity of cells expressing Schv anti 
bodies in soluble form in the periplasm was strongly depen 
dent on the E. coli strain used and on the growth conditions. 
With a 26-10 antibody, the maximum fluorescence intensity 
was obtained when the cells were grown at 25°C. Growth at 
Sub-physiological temperature has several beneficial effects. 
Expression of schvat low temperature (i.e., 25°C.) facilitates 
the proper folding of the scFv both directly, by slowing the 
folding pathway and indirectly by decreasing plasmid copy 
number to reduce expression load. Indeed, direct expression 
of sclv at 37° C. generally yields little or no soluble protein 
(for example see Gough et al., 1999). Outer membrane com 
position is also altered at non-physiological temperatures 
resulting in increased permeability (Martinez et al., 1999). 
Rather dramatic differences among various E. coli strains 
were noticed. Among several strains tested, the highest fluo 
rescence intensities were obtained in ABLETMC. A prelimi 













tein profile in this strain indicated that the higher fluorescent 
signal was not due to the pcnB mutation which reduces the 
copy number of ColE1 origin plasmids but rather, due to 
differences in cell envelope protein composition. In fact, the 
stronger staining of ABLETMC was not related to a higher 
level of protein expression relative to other strains as deduced 
by ELISA and Western blotting. 
Fluorescent labeling under hyperosmotic conditions, 
resulted in significantly greater fluorescence. A 5-7 fold 
increase in fluorescence was obtained when the cells were 
incubated in 5x PBS during labeling (a mean FL1 >150 com 
pared to 20-30 for cells incubated in regular PBS). However, 
the increased signal came at a cost, as cell viability decreased 
considerably. Such a decrease in viability may be undesirable 
when screening highly diverse libraries of proteins, whose 
expression may already have a deleterious effect on the host 
cell. Similarly, co-infection with filamentous phages such as 
M13KO7 induces the phage shock response, which among 
other things, results in an increase in outer membrane perme 
ability. M13 KO7 infection resulted in a 3-fold increase in the 
mean fluorescence of the population. However, as with hyper 
osmotic shock the viability of the culture, as determined by 
propidium iodide staining was somewhat decreased. 
Labeling of the cells with fluorescent ligand followed by 
incubation with a large excess of free ligand results in a 
time-dependent decrease in the mean fluorescence intensity. 
The rate of the fluorescence decay reflects the dissociation 
rate of the antibody-antigen complex (Daugherty et al., 
2000). For digoxin, the rate of fluorescence decay was found 
to be about 3-4 times slower compared to the dissociation rate 
measured with the purified antibody using BIACORE. The 
lower rate of fluorescence decay compared to the dissociation 
rate of the antibody/antigen complex in vitro stems from 
several effects including the collision frequency between 
ligands and cells, the concentration of antibody in the peri 
plasm and, of course, the rate of diffusion through the outer 
membrane (see Martinez et al., 1996) for an analysis ofkinet 
ics in the periplasmic space). As may be expected, the ratio of 
the rate of fluorescence decay in the periplasm relative to the 
in vitro determined krate is antigen dependent. 
Example 10 
Analysis and Screening of Repertoire Antibody 
Libraries by FACS 
Antibodies can be isolated de novo; i.e., without animal 
immunization, by Screening large, repertoire libraries that 
contain a wide variety of antibody sequences. The screening 
of such large libraries is well established (Nissim et al. 1994, 
Winter et al. 1994, Griffith et al. 1994, Knappik et al. 2000). 
So far, all the largeantibody repertoire libraries available have 
been constructed for use with phage display. However, librar 
ies constructed for phage display can also be used for the 
expression of proteins within the bacterial periplasmic space, 
eitheranchored to the inner membrane or in soluble form. In 
particular, for low protein copy number display on filamen 
tous bacteriophage, recombinant polypeptides are expressed 
as N-terminal fusions to pIII. During the course of phage 
biogenesis, pm fusions are first targeted to the periplasm and 
anchored in the inner membrane by a Small C-terminal por 
tion of pil. As phage are released, the scFV-plH fusion is 
incorporated alongside wild-type pii at the terminus of the 
phage, thereby concluding the assembly process (Rakonjac 
and Model, 1998; Rakonjac et al., 1999). In the most widely 
used vectors for phage display, an amber codon is placed 
between the N-terminal sclv and the plII gene. Thus, in a 
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suitable E. coli suppressor strain, full-length schv-pIII fusion 
protein is produced for displaying the sclv whereas in a 
non-Supressor Strain only soluble ScFv is expressed. Alterna 
tively, by including an inner membrane anchor peptide in the 
fusion, anchored expression can be achieved. 
The degree of Suppression with phage display varies with 
vector and strain but tends to allow only 10% read-through. 
Thus, as a consequence of the biology of phage display, all 
amber-codon containing libraries result in a degree of peri 
plasmic expression regardless of host. Hence, it was of great 
interest to explore whether FACS can aid the isolation of 
ligand binding proteins from pre-existing, highly diverse, 
naive libraries (Griffith et al., 1994; Vaughan et al., 1996; 
Sheets et al., 1998; Pini et al., 1998; de Haard et al., 1999; 
Knappik et al., 2000; Sblattero and Bradbury, 2000). 
Conventional Screening was performed of a phage library 
by phage panning enriched phage expressing scFVS specific 
for the cardiac glycoside digoxin from a naive antibody rep 
ertoire library. The panning process was performed on a BSA 
conjugate and the screening was performed on an ovalbumin 
conjugate to reduce the incidence of protein and hapten 
protein interface binders. 24 positive isolates from pan 4 
shared the same fingerprint and DNA sequencing of 6 clones 
confirmed the same heavy and light chain sequence (“dig1') 
with one of six (“dig2) having a unique HCDR3 and LCDR3 
combination. Repeated Screening of the phage library both 
under identical and under different conditions resulted only in 
the isolation of clones with the same DNA fingerprint. 
FACS analysis of the phage rescued in E. coli ABLETMC 
after each round of panning reveals an increase in mean 
fluorescence at round 3 which mirrors the phage ELISA sig 
nals. Significant enrichment of binding clones using a single 
round of FACS was obtained starting with the population 
obtained from the 3" round of phage panning. This result is 
consistent with the enrichment profiles obtained during the 
course of the panning experiment. FACS screening and sort 
ing 10° cells from rounds 3,4 and 5 resulted in the isolation of 
positive clones at a frequency of 30, 80 and 100% respec 
tively. 
Out of 14 clones isolated by FACS from the round 3 popu 
lation, 5 were found to be positive for binding to digoxin. 
Importantly, three of the clones corresponded to a different 
antibody that was missed by phage panning (herein known as 
“dig3’). The remaining 2 were the digl clone. This result 
demonstrates that FACS screening of libraries expressed in 
the periplasmic space and labeled with fluorescent ligands 
results in the isolation of clones that cannot be isolated by 
other library screening methodologies. 
Example 11 
Flow Cytometric Discrimination of E. coli 
Expressing the Fusarium Solani Lipase Cutinase 
Using Commercial Fluorescent Substrates 
This example demonstrates that commercially available 
fluorescent substrates can be used to specifically label E. coli 
cells displaying relevant enzymes in the periplasm. Surpris 
ingly, the soluble fluorescent product of these reactions is 
sufficiently retained within the cell to allow for the discrimi 
nation and selection of enzyme expressing E. coli from non 
enzyme expressing bacteria. 
The gene encoding Fusarium Solani lipase cutinase was 
constructed by total gene synthesis and placed downstream of 
the strong inducible promoterpBAD in plasmid pl3AD18Cm. 
Protein expression from the pBAD promoter is beneficial for 













1999). The resulting plasmid encoding the cutinase gene was 
designated pKG3-53-1. pKG3-53-1, and pBAD18Cm as a 
control, were both transformed into DH.5a. In this example, 
the ability to discriminate cells expressing cutinase (DH5a 
(pKG3-53-1)) from control cells was determined using two 
different commercially available substrates: Fluorescein 
dibutyrate or LysoSensor Green DND-189 (LSG) (both from 
Molecular Probes, OR). The latter is a positively charged 
fluorescent probe that detects pH changes in the cell occur 
ring due to ester hydrolysis by the enzyme. 
Cells were grown overnight with vigorous shaking at 37oC 
in terrific broth/chloramphenicol 50 ug/ml (TB/Cm). Subcul 
tures were made from 100 ul of overnight culture in 10 ml of 
TB/Cm(50 ug/ml). These subcultures were grown with vig 
orous shaking at 37°C. to ODoo-0.6. Four ml aliquots of the 
subcultures were pelleted at 3650 rpm for 20 minutes in a 
Beckman Allegra 6R Centrifuge. The supernatant was 
removed, and the pellets were resuspended in 4 ml of M9 
minimal media containing 0.2% glucose and chlorampheni 
col (Cm) at 50 lug/ml. Arabinose, from a 20% stock, was 
added to a final concentration of 0.2%. The cultures were 
induced at 25°C. with vigorous shaking for 4 hours. Subse 
quently, 2 ml. aliquots of the induced cultures were pelleted at 
8000 rpm for 10 minutes in an Eppendorf 5415C Centrifuge, 
washed with fresh media and pelleted again at 8000 rpm for 
10 min. The washed pellets were resuspended in M9 salts 
media without glucose to an optical density ODoo 1.0. The 
stock solution was diluted 1:10 and 1 ml of the diluted cell 
suspension was mixed with 0.1 ml 0.1 mM Fluorescein dibu 
tyrate (FDB) stock solution in dimethyl sulfoxide (DMSO). 
The final FDB concentration was 10 uM. Reactions were 
allowed to proceed at 37°C. for 30 minutes. The labeled cells 
were immediately analyzed on a Becton Dickinson FACSort 
equipped with an Ar 488 nm laser. The fluorescence distribu 
tion of the cutinase expressing cells and the control cells is 
shown in FIG. 4A. 
The utility of a second probe for the discrimination 
between positive (enzyme expressing) and control cells was 
also examined. E. coli expressing cutinase from the pKG3 
53-4 plasmid, and negative cells (expressing the umnodified 
pBAD18Cm plasmid) were grown, induced and washed as 
above. The pellet was washed with 1% sucrose, pelleted 
again, and resuspended in fresh 1% Sucrose to ODoo-1.0. 
This stock solution of cells was kept on ice. 
For labeling, a LysoSensor Green DND-189 (LSG, 
Molecular Probes) stock solution was prepared to 1 mM in 
DMSO. Also, a 1 M 4-Nitrophenyl Butyrate stock solution 
was prepared in DMSO. Cell labeling was initiated by first 
diluting the cell stock solution, adding the LSG to a final 
concentration of 1 uM and diluting the 4-Nitrophenyl 
Butyrate 1:1000 to give a final concentration of 1 uM. The 
enzymatic hydrolysis of 4-Nitrophenyl Butyrate by the cells 
was allowed to proceed at 25°C. for 5 minutes and the cells 
were then immediately analyzed on a Becton Dickinson FAC 
Sort as above. 
All of the methods disclosed and claimed herein can be 
made and executed without undue experimentation in light of 
the present disclosure. While the compositions and methods 
of this invention have been described in terms of preferred 
embodiments, it will be apparent to those of skill in the art that 
variations may be applied to the methods and in the steps or in 
the sequence of steps of the method described herein without 
departing from the concept, spirit and scope of the invention. 
More specifically, it will be apparent that certainagents which 
are both chemically and physiologically related may be Sub 
stituted for the agents described herein while the same or 
similar results would beachieved. All such similar substitutes 
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and modifications apparent to those skilled in the art are 
deemed to be within the spirit, scope and concept of the 
invention as defined by the appended claims. 
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SEQUENCE LISTING 






SEO ID NO 1 
LENGTH: 17 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE; 
Primer 
<4 OOs SEQUENCE: 1 
Caggaaacag ctatgac 
SEO ID NO 2 
LENGTH: 17 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE; 
Primer 
<4 OOs SEQUENCE: 2 
gaattittctg. tatgagg 
SEO ID NO 3 
LENGTH: 18 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE; 
Primer 
<4 OOs SEQUENCE: 3 
gcc acct cog cctogalacc 
SEO ID NO 4 
LENGTH: 17 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE; 
Primer 
<4 OOs SEQUENCE: 4 
ctatocggcc cc attca 
5 
10 
OTHER INFORMATION: Description of Artificial Sequence: 
OTHER INFORMATION: Description of Artificial Sequence: 
OTHER INFORMATION: Description of Artificial Sequence: 
OTHER INFORMATION: Description of Artificial Sequence: 
36 
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- Continued 
<210s, SEQ ID NO 5 
&211s LENGTH: 5 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<4 OOs, SEQUENCE: 5 
aaaaa. 
<210s, SEQ ID NO 6 
&211s LENGTH: 39 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<4 OOs, SEQUENCE: 6 
gaaggagata tacatatgaa actgacaa.ca catcatcta 
<210s, SEQ ID NO 7 
&211s LENGTH: 45 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<4 OO > SEQUENCE: 7 
Ctgggc catg gcc.ggctggg cct cqctgct act ctggtcg caacc 
<210s, SEQ ID NO 8 
&211s LENGTH: 7 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Peptide 
<4 OOs, SEQUENCE: 8 
Glin Thir Thr His Wall Pro Pro 
1. 5 
<210s, SEQ ID NO 9 
&211s LENGTH: 7 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Peptide 
<4 OOs, SEQUENCE: 9 
Glin Thir Thr His Wall Pro Pro 
1. 5 
<210s, SEQ ID NO 10 
&211s LENGTH: 7 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Peptide 
<4 OOs, SEQUENCE: 10 
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- Continued 
<210s, SEQ ID NO 11 
&211s LENGTH: 7 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Peptide 
<4 OOs, SEQUENCE: 11 
Glin Thir Thr His Lieu. Pro Thir 
1. 5 
<210s, SEQ ID NO 12 
&211s LENGTH: 7 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Peptide 
<4 OOs, SEQUENCE: 12 
Glin. Thir Thir His Thr Pro Pro 
1. 5 
<210s, SEQ ID NO 13 
&211s LENGTH: 7 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Peptide 
<4 OO > SEQUENCE: 13 
Glin. Thir Thir His Thr Pro Pro 
1. 5 
<210s, SEQ ID NO 14 
&211s LENGTH: 7 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Peptide 
<4 OOs, SEQUENCE: 14 
Glin. Thir Thir His Ile Pro Thir 
1. 5 
<210s, SEQ ID NO 15 
&211s LENGTH: 7 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Peptide 
<4 OOs, SEQUENCE: 15 
Glin Thir Thr His Wall Pro Pro 
1. 5 
<210s, SEQ ID NO 16 
&211s LENGTH: 7 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
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- Continued 
<4 OOs, SEQUENCE: 16 
Glin Thir Thr His Wall Pro Ala 
1. 5 
<210s, SEQ ID NO 17 
&211s LENGTH: 7 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Peptide 
<4 OOs, SEQUENCE: 17 
Glin Thir Thr His Ile Pro Ala 
1. 5 
<210s, SEQ ID NO 18 
&211s LENGTH: 7 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Peptide 
<4 OOs, SEQUENCE: 18 
Glin Thir Thr His Lieu. Pro Ala 
1. 5 
<210s, SEQ ID NO 19 
&211s LENGTH: 7 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Peptide 
<4 OOs, SEQUENCE: 19 
Gln Thr Thr His Val Pro Cys 
1. 5 
<210s, SEQ ID NO 2 O 
&211s LENGTH: 741 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 





gatatt caga tigacacagac tacatcct co citgtctgcct citctgggaga cagagt cacc 6 O 
atcagttgca gggcaagt cagga cattagg aattatttaa actggitatica gcagaalacca 12 O 
gatggaactg ttaaactic ct gatctactac acatcaagat tacagt cagg agt cocatca 18O 
aggttcagtg gcagtgggtc taacagat tatt Ctctica C cattagcaa C caggagcaa. 24 O 
gaagat attg gCactt actt ttgccaacag ggtaatacgc titc.cgtggac gttcggtgga 3OO 
ggcaccalagc tiggaaataaa acgtggtggit ggtggttctg gtggtggtgg ttctggcggc 360 
ggcggctic.cg gtggtggtgg atc.cgagg to Caactgcaac agtctggacc tagdtggtg 42O 
aagcctgggg cct cagtgaa gattt Cotgc aaagattctg gctacgcatt Cagtagctict 48O 
tggatgaact gggtgaagca gaggcctgga Cagggit ctitg agtggattgg acggattitat 54 O 
Cctggagatg gagatact aa ctacaatggg aagttcaagg gcaaggccac actgactgca 6OO 
gacaaatcct C cagcacagc ctacatgcag Ctcagcagcc tacctctgt ggactctgcg 660 
42 
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- Continued 
gtct atttct gtgcaagatc ggggttacta C9ttatgcta tigact actgggg.tcaagga 72 O 
acct cagt ca ccgt.ct cotc g 74.1 
<210s, SEQ ID NO 21 
&211s LENGTH: 247 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Peptide 
<4 OOs, SEQUENCE: 21 
Asp Ile Gln Met Thr Glin Thir Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1. 5 1O 15 
Asp Arg Val Thir Ile Ser Cys Arg Ala Ser Glin Asp Ile Arg Asn Tyr 
2O 25 3 O 
Lieu. Asn Trp Tyr Glin Glin Llys Pro Asp Gly Thr Val Llys Lieu. Lieu. Ile 
35 4 O 45 
Tyr Tyr Thr Ser Arg Lieu. Glin Ser Gly Val Pro Ser Arg Phe Ser Gly 
SO 55 60 
Ser Gly Ser Gly Thr Asp Tyr Ser Lieu. Thir Ile Ser Asn Glin Glu Gln 
65 70 7s 8O 
Glu Asp Ile Gly Thr Tyr Phe Cys Glin Glin Gly Asn Thr Lieu Pro Trp 
85 90 95 
Thir Phe Gly Gly Gly Thr Llys Lieu. Glu Ile Lys Arg Gly Gly Gly Gly 
1OO 105 11 O 
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
115 12 O 125 
Glu Val Glin Lieu. Glin Glin Ser Gly Pro Glu Lieu Val Llys Pro Gly Ala 
13 O 135 14 O 
Ser Val Lys Ile Ser Cys Lys Asp Ser Gly Tyr Ala Phe Ser Ser Ser 
145 150 155 160 
Trp Met Asn Trp Wall Lys Glin Arg Pro Gly Glin Gly Lieu. Glu Trp Ile 
1.65 17O 17s 
Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thir Asn Tyr Asn Gly Llys Phe 
18O 185 19 O 
Lys Gly Lys Ala Thr Lieu. Thir Ala Asp Llys Ser Ser Ser Thir Ala Tyr 
195 2OO 2O5 
Met Glin Leu Ser Ser Lieu. Thir Ser Val Asp Ser Ala Val Tyr Phe Cys 
21 O 215 22O 
Ala Arg Ser Gly Lieu. Lieu. Arg Tyr Ala Met Asp Tyr Trp Gly Glin Gly 
225 23 O 235 24 O 
Thir Ser Wall. Thir Wal Ser Ser 
245 
<210s, SEQ ID NO 22 
&211s LENGTH: 741 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Primer 
<4 OOs, SEQUENCE: 22 
gatatt caga tigacacagac tacatcct co citgtctgcct citctgggaga cagagt cacc 6 O 
gtcagttgca gggcaagt ca gga cattagg aattatttaa actggitatica gcagaalacca 12 O 








































SEQ ID NO 23 
LENGTH: 247 
TYPE : 
ORGANISM: Artificial Sequence 
FEATURE: 




















































Thr Val Ser Cys Arg 
Tyr Glin Gln Lys Pro 
4 O 
Ser Arg Lieu. Glin Pro 
Gly Thr Asp Tyr Ser 
70 
Gly Thr Tyr Phe Cys 
85 
Gly Gly Thr Llys Lieu. 
Gly Gly Ser Gly Gly 
12 O 
Lieu. Glin Glin Ser Gly 
135 
Ile Ser Cys Lys Asp 
150 
Trp Wall Lys Glin Arg 
1.65 
Tyr Pro Gly Asp Gly 
18O 
Ala Ile Lieu. Thir Ala 
Ser Ser Lieu. Thir Ser 
215 
Gly Lieu. Lieu. Arg Tyr 
23 O 
Thir Wal Ser Ser 
245 









Ser Ser Lieu. 
1O 
Ala Ser Glin 
25 
Asp Gly Thr 
Gly Val Pro 
Lieu. Thir Ile 
7s 
Gln Glin Gly 
Glu Ile Llys 
105 
Gly Gly Ser 
Pro Gu Luell 
Ser Gly Tyr 
155 
Pro Gly Glin 
Asp Ser Asn 
185 
Asp Llys Ser 
Val Asp Ser 
Ala Met Asp 
235 
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- Continued 
<210s, SEQ ID NO 24 
&211s LENGTH: 741 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Primer 
<4 OOs, SEQUENCE: 24 
gatatt caga tigacacagac tacatcct co citgtctgcct citctgggaga cagagt cacc 6 O 
gtcagttgca gggcaagt ca gga cattagg aattatttaa actggitatica gcagaalacca 12 O 
gacggaactg ttaaattic ct gatctactac acatcaagat tactgcc agg agt cocatca 18O 
aggttcagtg gcagtgggtc taacagat tatt CCCtca C cattaacaa Cctggagcag 24 O 
gaagat attg gCactt actt ttgccaacag ggcaatacgc Ctc.cgtggac gttcggtgga 3OO 
ggcaccalagc tiggaaataaa acgtggtgga ggtggttctg atggtggtgg ttctggcggc 360 
ggcggctic.cg gtggtggtgg atc.cgagg to Caactgcaac agtctggacc tagdtggtg 42O 
aagcctgggg cct cagtgaa gattt Cotgc aaagattctg gctacgcatt Caatagctict 48O 
tggatgaact gggtgaagca gaggcctgga Cagggit ctitg agtggattgg acggattitat 54 O 
Cctggagatg gagattictaa ctacaatggg aaatticgagg gcaaggc.cat actgacagca 6OO 
gacaaatcct C cagcacagc ctacatgcag Ctcagcagcc tacctctgt ggactctgcg 660 
gtct atttct gtgcaagatc ggggttgcta C9ttatgcta tigact actgggg.tcaagga 72 O 
acct cagt ca ccgt.ct cotc g 74.1 
<210s, SEQ ID NO 25 
&211s LENGTH: 247 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Peptide 
<4 OOs, SEQUENCE: 25 
Asp Ile Gln Met Thr Glin Thir Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1. 5 1O 15 
Asp Arg Val Thr Val Ser Cys Arg Ala Ser Glin Asp Ile Arg Asn Tyr 
2O 25 3 O 
Lieu. Asn Trp Tyr Glin Glin Llys Pro Asp Gly Thr Val Llys Phe Lieu. Ile 
35 4 O 45 
Tyr Tyr Thr Ser Arg Lieu Lleu Pro Gly Val Pro Ser Arg Phe Ser Gly 
SO 55 60 
Ser Gly Ser Gly Thr Asp Tyr Ser Lieu. Thir Ile Asn Asn Lieu. Glu Gln 
65 70 7s 8O 
Glu Asp Ile Gly Thr Tyr Phe Cys Glin Glin Gly Asn Thr Pro Pro Trp 
85 90 95 
Thir Phe Gly Gly Gly Thr Llys Lieu. Glu Ile Lys Arg Gly Gly Gly Gly 
1OO 105 11 O 
Ser Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
115 12 O 125 
Glu Val Glin Lieu. Glin Glin Ser Gly Pro Glu Lieu Val Llys Pro Gly Ala 
13 O 135 14 O 
Ser Val Lys Ile Ser Cys Lys Asp Ser Gly Tyr Ala Phe Asin Ser Ser 
145 150 155 160 
Trp Met Asn Trp Wall Lys Glin Arg Pro Gly Glin Gly Lieu. Glu Trp Ile 
1.65 17O 17s 
48 
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49 50 
- Continued 
Gly Arg Ile Tyr Pro ASn 
18O 
Gly Asp Gly Asp Ser 
185 










Luell Ser Ser Lell Ser Val Asp Ser 
Ala 
225 
Lell Ala Met 
23 O 
Arg Ser Gly Lieu Arg Tyr Asp 
235 
Thir Wall. Thir Wall 
245 
Ser Ser Ser 
What is claimed is: 
1. An isolated nucleic acid encoding an isolated antibody or 
fragment thereof that binds immunologically to Bacillus 
anthracis protective antigen and comprises the variable light 
and variable heavy chain of SEQID NO:21, with the excep 
tion that the variable light and variable heavy chain collec 
tively comprise at least three modifications selected from the 
group consisting of I21V, S22G, L33S, Q38R, L46F, Q55L, 
S56P. T74A, S76N, Q78L, L94P S7P K19R, S30N, T57S, 
K62R, K64E, T68I, and M80L, wherein said I21V, S22G, 
L33S, Q38R, L46F, Q55L, S56P. T74A, S76N, Q78L and 
L94P are in the variable light chain and wherein said S7P. 
K19R, S30N, T57S, K62R, K64E, T68I and M80L are in the 
variable heavy chain. 
Tyr Asn Gly Lys 
19 O 
Ser Thir Ala 
Val Tyr Phe 






2. The isolated nucleic acid of claim 1, further defined as 
encoding the variable light chain of SEQID NO:23 or SEQ 
ID NO:25. 
3. The isolated nucleic acid of claim 1, further defined as 
encoding the variable heavy chain of SEQID NO:23 or SEQ 
ID NO:25. 
4. The isolated nucleic acid of claim 1, further defined as 
encoding the polypeptide of SEQID NO:23. 
5. The isolated nucleic acid of claim 1, further defined as 
encoding the polypeptide of SEQID NO:25. 
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